US20110027371A1 - Nanoparticulate statin formulations and novel statin combinations - Google Patents
Nanoparticulate statin formulations and novel statin combinations Download PDFInfo
- Publication number
- US20110027371A1 US20110027371A1 US11/367,716 US36771606A US2011027371A1 US 20110027371 A1 US20110027371 A1 US 20110027371A1 US 36771606 A US36771606 A US 36771606A US 2011027371 A1 US2011027371 A1 US 2011027371A1
- Authority
- US
- United States
- Prior art keywords
- less
- statin
- composition
- group
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to nanoparticulate compositions comprising statin, preferably lovastatin or simvastatin, and novel statin combinations.
- the nanoparticulate statin particles preferably have an effective average particle size of less than about 2000 nm.
- this invention includes novel combinations of statins and other cholesterol lowering agents and methods of using the same.
- Nanoparticulate active agent compositions are particles consisting of a poorly soluble therapeutic or diagnostic agent having adsorbed onto, or associated with, the surface thereof a non-crosslinked surface stabilizer. Many factors can affect bioavailability including the dosage form and various properties, e.g., dissolution rate of the drug. Poor bioavailability is a significant problem encountered in the development of pharmaceutical compositions, particularly those containing an active ingredient that is poorly soluble in water. By decreasing the particle size of an active agent, the surface area of the composition is increased, thereby generally resulting in an increased bioavailability.
- the '684 patent does not teach nanoparticulate compositions of statins.
- nanoparticulate active agent compositions are described in, for example, U.S. Pat. Nos. 5,518,187 and 5,862,999, both for “Method of Grinding Pharmaceutical Substances;” U.S. Pat. No. 5,718,388, for “Continuous Method of Grinding Pharmaceutical Substances;” and U.S. Pat. No. 5,510,118 for “Process of Preparing Therapeutic Compositions Containing Nanoparticles.”
- Nanoparticulate active agent compositions are also described, for example, in U.S. Pat. No. 5,298,262 for “Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Sterilization;” No. 5,302,401 for “Method to Reduce Particle Size Growth During Lyophilization;” No. 5,318,767 for “X-Ray Contrast Compositions Useful in Medical Imaging;” 5,326,552 for “Novel Formulation For Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-ionic Surfactants;” No. 5,328,404 for “Method of X-Ray Imaging Using Iodinated Aromatic Propanedioates;” No.
- Amorphous small particle compositions are described, for example, in U.S. Pat. No. 4,783,484 for “Particulate Composition and Use Thereof as Antimicrobial Agent;” No. 4,826,689 for “Method for Making Uniformly Sized Particles from Water-Insoluble Organic Compounds;” No. 4,997,454 for “Method for Making Uniformly-Sized Particles From Insoluble Compounds;” No. 5,741,522 for “Ultrasmall, Non-aggregated Porous Particles of Uniform Size for Entrapping Gas Bubbles Within and Methods;” and No. 5,776,496, for “Ultrasmall Porous Particles for Enhancing Ultrasound Back Scatter.”
- statins drugs collectively known as statins or vastatins
- statins have been introduced to reduce serum LDL cholesterol levels (representative examples of these drugs are detailed in The Merck Index ).
- High LDL cholesterol levels have been shown to be an important risk factor in the development of arteriosclerosis and ischaemic heart disease.
- Statins have been found to lower serum LDL cholesterol levels in a dose dependent manner. Additionally, these drugs lower serum triglyceride levels, which is another risk factor for heart disease.
- Statins lower serum LDL cholesterol levels by competitive inhibition of 3-hydroxyl-3-methylglutaryl-Coenzyme A reductase (HMG-COA reductase), an enzyme involved in the biosynthesis of cholesterol.
- HMG-COA reductase 3-hydroxyl-3-methylglutaryl-Coenzyme A reductase
- statins By binding tightly to the active site of the enzyme, statins block the reduction of HMG-CoA, a step necessary in the biosynthesis of cholesterol. This inhibition of cholesterol biosynthesis by a statin results in a decrease in the production and secretion of LDL cholesterol. In addition, the upregulation of LDL receptors, especially in the liver, leads to the removal of LDLs from the serum. Thus, by reducing the production of LDL cholesterol and by causing LDL cholesterol to be removed from the serum, statins effectively reduce overall serum LDL cholesterol levels.
- statins typically have high oral availability and high hepatic extraction during their first pass through the liver. Statins have been associated with significant liver toxicity.
- the present invention relates to nanoparticulate active agent compositions comprising at least one statin, such as lovastatin or simvastatin, and novel statin combinations.
- the compositions preferably comprise at least one statin and at least one surface stabilizer adsorbed on or associated with the surface of the one or more statin particles.
- the nanoparticulate statin particles preferably have an effective average particle size of less than about 2000 nm.
- compositions comprising a nanoparticulate statin composition of the invention.
- the pharmaceutical compositions preferably comprise at least one statin, at least one surface stabilizer, and at least one pharmaceutically acceptable carrier, as well as any desired excipients known to those in the art and formulated into the dosage form desired.
- statins and at least one other cholesterol lowering agent are described and methods of using the same are taught.
- Another aspect of the invention is directed to a nanoparticulate statin composition having improved pharmacokinetic profiles as compared to conventional microcrystalline statin formulations, such as improved T max , C max , and AUC parameters.
- One embodiment of the invention encompasses a statin composition, wherein the pharmacokinetic profile of the statin is not substantially affected by the fed or fasted state of a subject ingesting the composition, preferably as defined by C. and AUC guidelines given by the U.S. Food and Drug Administration and/or the corresponding European regulatory agency (EMEA).
- EMEA European regulatory agency
- the invention encompasses a statin composition of the invention, wherein administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state, in particular as defined by C max and AUC guidelines given by the U.S. Food and Drug Administration and the corresponding European regulatory agency (EMEA).
- EMEA European regulatory agency
- nanoparticulate statin compositions which, as compared to conventional non-nanoparticulate formulations of the same statin, preferably have one or more of the following properties: (1) smaller tablet or other solid dosage form size; (2) smaller doses of drug required to obtain the same pharmacological effect; (3) increased bioavailability; (4) an increased rate of dissolution for the nanoparticulate statin compositions; and (6) bioadhesive statin compositions.
- This invention further discloses a method of making a nanoparticulate statin composition according to the invention.
- Such method comprises contacting one or more statins and at least one surface stabilizer for a time and under conditions sufficient to provide a nanoparticulate statin composition.
- the one or more surface stabilizers can be contacted with the statin before, preferably during, or after size reduction of the statin.
- the present invention is also directed to methods of treatment using the nanoparticulate statin compositions of the invention for conditions such as hypercholesterolemia, hypertriglyceridemia, coronary heart disease, and peripheral vascular disease (including symptomatic carotid artery disease).
- the compositions of the invention can be used as adjunctive therapy to diet for the reduction of LDL-C, total-C, triglycerides, and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb).
- the compositions can be used as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia).
- Markedly elevated levels of serum tryglycerides may increase the risk of developing pancreatitis.
- Other diseases that may be directly or indirectly associated with elevated, uncontrolled cholesterol metabolism, e.g., restenosis and Alzheimer's disease, may also be treated with the compositions of this invention.
- Other methods of treatment using the nanoparticulate statin compositions of the present invention are know to those of skill in the art.
- Such methods comprise administering to a subject a therapeutically effective amount of a nanoparticulate statin pharmaceutical composition according to the invention.
- the present invention relates to nanoparticulate active agent compositions comprising at least one statin, such as lovastatin or simvastatin, and novel statin combinations.
- the compositions preferably comprise at least one statin and at least one surface stabilizer adsorbed on or associated with the surface of the statin particles.
- the nanoparticulate statin particles preferably have an effective average particle size of less than about 2000 nm.
- compositions of nanoparticulate statins decrease the amount of drug needed and the amount that escapes from the liver and this, in turn, decreases adverse side effects while providing maximum dose response. Additionally, a longer plasma half-life is believed to be associated with nanoparticulate statin compositions of the invention. Moreover, increasing the duration of effect of the HMG-CoA reductase inhibitor is expected to result in even lower serum cholesterol levels, with a further reduction in dose expected.
- the rate of dissolution of a particulate drug can increase with increasing surface area, e.g., decreasing particle size. Consequently, methods of making finely divided drugs have been studied and efforts have been made to control the size and size range of drug particles in pharmaceutical compositions.
- nanoparticulate active agent formulations suitable for administration as a pharmaceutical require formulation of the active ingredient into a colloidal dispersion exhibiting the acceptable nanoparticle size range and the stability to maintain such size range and not agglomerate.
- Merely increasing surface area by decreasing particle size does not assure success.
- Further challenges include forming solid dose forms redispersible into the nanoparticle form upon administration to the patient to maintain the benefit of the nanoparticle statin over the traditional dosage form.
- nanoparticulate statin formulations of the invention as compared to conventional non-nanoparticulate formulations of the same statin preferably include, but are not limited to: (1) smaller tablet or other solid dosage form size; (2) smaller doses of drug required to obtain the same pharmacological effect; (3) increased bioavailability; (4) substantially similar pharmacokinetic profiles of the nanoparticulate statin compositions when administered in the fed versus the fasted state; (5) improved pharmacokinetic profiles; (6) bioequivalency of the nanoparticulate statin compositions when administered in the fed versus the fasted state; (7) an increased rate of dissolution for the nanoparticulate statin compositions; (8) bioadhesive statin compositions; and (9) the nanoparticulate statin compositions can be used in conjunction with other active agents.
- the present invention also includes nanoparticulate statin compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers.
- the compositions can be formulated for parenteral injection (e.g., intravenous, intramuscular, or subcutaneous), oral administration in solid, liquid, or aerosol form, vaginal, nasal, rectal, ocular, local (powders, ointments or drops), buccal, intracisternal, intraperitoneal, or topical administration, and the like.
- a preferred dosage form of the invention is a solid dosage form, although any pharmaceutically acceptable dosage form can be utilized.
- Exemplary solid dosage forms include, but are not limited to, tablets, capsules, sachets, lozenges, powders, pills, or granules.
- the solid dosage form can be, for example, a fast melt dosage form, controlled release dosage form, lyophilized dosage form, delayed release dosage form, extended release dosage form, pulsatile release dosage form, mixed immediate release and controlled release dosage form, or a combination thereof.
- a solid dose tablet formulation is preferred.
- “About” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which the term is used. If there are uses of the term which are not clear to persons of ordinary skill in the art given the context in which it is used, “about” will mean up to plus or minus 10% of the particular term. “Conventional” or “non-nanoparticulate active agent” shall mean an active agent which is solubilized or which has an effective average particle size of greater than about 2 microns.
- “Poorly water soluble drugs” as used herein means those having a solubility of less than about 30 mg/ml, preferably less than about 20 mg/ml, preferably less than about 10 mg/ml, or preferably less than about 1 mg/ml. Such drugs tend to be eliminated from the gastrointestinal tract before being absorbed into the circulation. Moreover, poorly water soluble drugs tend to be unsafe for intravenous administration techniques, which are used primarily in conjunction with highly water soluble drug substances.
- stable includes, but is not limited to, one or more of the following parameters: (1) that the statin particles do not appreciably flocculate or agglomerate due to interparticle attractive forces, or otherwise significantly increase in particle size over time; (2) that the physical structure of the statin particles is not altered over time, such as by conversion from an amorphous phase to crystalline phase; (3) that the statin particles are chemically stable; and/or (4) where the statin has not been subject to a heating step at or above the melting point of the statin in the preparation of the nanoparticles of the invention.
- “Therapeutically effective amount” as used herein with respect to a drug dosage shall mean that dosage that provides the specific pharmacological response for which the drug is administered in a significant number of subjects in need of such treatment. It is emphasized that “therapeutically effective amount,” administered to a particular subject in a particular instance will not always be effective in treating the diseases described herein, even though such dosage is deemed a ‘therapeutically effective amount’ by those skilled in the art. It is to be further understood that drug dosages are, in particular instances, measured as oral dosages, or with reference to drug levels as measured in blood.
- statin compositions of the invention preferably exhibit increased bioavailability, at the same dose of the same statin, require smaller doses, and show longer plasma half-life as compared to prior conventional statin formulations.
- statin compositions have enhanced bioavailability such that the statin dosage can be reduced, resulting in a decrease in toxicity associated with such statins. It has been surprisingly found in the present invention that stable compositions of nanoparticulate statins can be formed that permit therapeutic levels at desirably lower dosage.
- statin compositions of the invention can enable a smaller solid dosage size. This is particularly significant for patient populations such as the elderly, juvenile, and infant.
- the invention also preferably provides statin compositions having a desirable pharmacokinetic profile when administered to mammalian subjects.
- the desirable pharmacokinetic profile of the statin compositions preferably includes, but is not limited to: (1) that the T max of a statin when assayed in the plasma of a mammalian subject following administration is preferably less than the T max for a conventional, non-nanoparticulate form of the same statin, administered at the same dosage; (2) that the C max of a statin when assayed in the plasma of a mammalian subject following administration is preferably greater than the C max for a conventional, non-nanoparticulate form of the same statin, administered at the same dosage; and/or (3) that the AUC of a statin when assayed in the plasma of a mammalian subject following administration, is preferably greater than the AUC for a conventional, non-nanoparticulate form of the same statin, administered at the same dosage.
- the desirable pharmacokinetic profile is the pharmacokinetic profile measured after the initial dose of a statin.
- the compositions can be formulated in any way as described below and as known to those of skill in the art.
- a preferred statin composition of the invention exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same statin, administered at the same dosage, a T max not greater than about 90%, not greater than about 80%, not greater than about 70%, not greater than about 60%, not greater than about 50%, not greater than about 30%, not greater than about 25%, not greater than about 20%, not greater than about 15%, or not greater than about 10% of the T max , exhibited by the non-nanoparticulate formulation of the same statin.
- a preferred statin composition of the invention exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same statin, administered at the same dosage, a C max which is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% greater than the C max exhibited by the non-nanoparticulate formulation of the same statin.
- a preferred statin composition of the invention exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same statin, administered at the same dosage, an AUC which is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% greater than the AUC exhibited by the non-nanoparticulate formulation of the same statin.
- Any formulation giving the desired pharmacokinetic profile is suitable for administration according to the present methods.
- Exemplary types of formulations giving such profiles are liquid dispersions, gels, aerosols, ointments, creams, solid dose forms, etc. of a nanoparticulate statin.
- the invention encompasses a statin composition wherein the pharmacokinetic profile of the statin is preferably not substantially affected by the fed or fasted state of a subject ingesting the composition, when administered to a human. This means that there is no substantial difference in the quantity of drug absorbed or the rate of drug absorption when the nanoparticulate statin compositions are administered in the fed versus the fasted state.
- the invention also encompasses a statin composition in which administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state.
- “Bioequivalency” is preferably established by a 90% Confidence Interval (CI) of between 0.80 and 1.25 for both C max and AUC under U.S. Food and Drug Administration regulatory guidelines, or a 90% CI for AUC of between 0.80 to 1.25 and a 90% CI for C max of between 0.70 to 1.43 under the European EMEA regulatory guidelines (T max is not relevant for bioequivalency determinations under USFDA and EMEA regulatory guidelines).
- lovastatin given under fasting conditions has been shown to result in plasma concentrations of total inhibitors that were on average about two-thirds those found when lovastatin was administered immediately after a standard test meal. This significant difference of about 33% in absorption observed with conventional statin formulations is undesirable.
- the nanoparticulate statin formulations of the invention alleviate this problem, as the nanoparticulate statin formulations of the invention reduce differences in or preferably do not produce significantly different, absorption levels when administered under fed as compared to fasting conditions.
- Benefits of a dosage form which substantially eliminates the effect of food include an increase in subject convenience, thereby increasing subject compliance, as the subject does not need to ensure that they are taking a dose either with or without food. This is significant, as with poor subject compliance an increase in the medical condition for which the drug is being prescribed may be observed.
- the difference in absorption of the statin compositions of the invention, when administered in the fed versus the fasted state, preferably is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, or less than about 3%.
- statin compositions of the invention preferably have unexpectedly dramatic dissolution profiles. Rapid dissolution of an administered active agent is preferable, as faster dissolution generally leads to faster onset of action and greater bioavailability. To improve the dissolution profile and bioavailability of statins it would be useful to increase the drug's dissolution so that it could attain a level close to 100%.
- the statin compositions of the invention preferably have a dissolution profile in which within about 5 minutes at least about 20% of the composition is dissolved. In other embodiments of the invention, at least about 30% or about 40% of the statin composition is dissolved within about 5 minutes. In yet other embodiments of the invention, preferably at least about 40%, about 50%, about 60%, about 70%, or about 80% of the statin composition is dissolved within about 10 minutes. Finally, in another embodiment of the invention, preferably at least about 70%, about 80%, about 90%, or about 100% of the statin composition is dissolved within about 20 minutes.
- Dissolution is preferably measured in a medium which is discriminating. Such a dissolution medium will produce two very different dissolution curves for two products having very different dissolution profiles in gastric juices; i.e., the dissolution medium is predictive of in vivo dissolution of a composition.
- An exemplary dissolution medium is an aqueous medium containing the surfactant sodium lauryl sulfate at 0.025 M. Determination of the amount dissolved can be carried out by spectrophotometry. The rotating blade method (European Pharmacopoeia) can be used to measure dissolution.
- statin compositions of the invention preferably redisperse such that the effective average particle size of the redispersed statin particles is less than about 2 microns. This is significant, as if upon administration the nanoparticulate statin compositions of the invention did not redisperse to a substantially nanoparticulate particle size, then the dosage form may lose the benefits afforded by formulating the statin into a nanoparticulate particle size.
- nanoparticulate active agent compositions benefit from the small particle size of the active agent; if the active agent does not redisperse into the small particle sizes upon administration, then “clumps” or agglomerated active agent particles are formed, owing to the extremely high surface free energy of the nanoparticulate system and the thermodynamic driving force to achieve an overall reduction in free energy. With the formation of such agglomerated particles, the bioavailability of the dosage form may fall well below that observed with the liquid dispersion form of the nanoparticulate active agent.
- the nanoparticulate statin compositions of the invention preferably exhibit dramatic redispersion of the nanoparticulate statin particles upon administration to a mammal, such as a human or animal, as demonstrated by reconstitution/redispersion in a biorelevant aqueous media such that the effective average particle size of the redispersed statin particles is less than about 2 microns.
- biorelevant aqueous media can be any aqueous media that exhibit the desired ionic strength and pH, which form the basis for the biorelevance of the media.
- the desired pH and ionic strength are those that are representative of physiological conditions found in the human body.
- Such biorelevant aqueous media can be, for example, aqueous electrolyte solutions or aqueous solutions of any salt, acid, or base, or a combination thereof, which exhibit the desired pH and ionic strength.
- Biorelevant pH is well known in the art.
- the pH ranges from slightly less than 2 (but typically greater than 1) up to 4 or 5.
- the pH can range from 4 to 6, and in the colon it can range from 6 to 8.
- Biorelevant ionic strength is also well known in the art. Fasted state gastric fluid has an ionic strength of about 0.1M while fasted state intestinal fluid has an ionic strength of about 0.14. See e.g., Lindahl et al., “Characterization of Fluids from the Stomach and Proximal Jejunum in Men and Women,” Pharm. Res., 14 (4): 497-502 (1997).
- pH and ionic strength of the test solution is more critical than the specific chemical content. Accordingly, appropriate pH and ionic strength values can be obtained through numerous combinations of strong acids, strong bases, salts, single or multiple conjugate acid-base pairs (i.e., weak acids and corresponding salts of that acid), monoprotic and polyprotic electrolytes, etc.
- electrolyte solutions can be, but are not limited to, HCl solutions, ranging in concentration from about 0.001 to about 0.1 M, and NaCl solutions, ranging in concentration from about 0.001 to about 0.1 M, and mixtures thereof.
- electrolyte solutions can be, but are not limited to, about 0.1 M HCl or less, about 0.01 M HCl or less, about 0.001 M HCl or less, about 0.1 M NaCl or less, about 0.01 M NaCl or less, about 0.001 M NaCl or less, and mixtures thereof.
- 0.01 M HCl and/or 0.1 M NaCl are most representative of fasted human physiological conditions, owing to the pH and ionic strength conditions of the proximal gastrointestinal tract.
- Electrolyte concentrations of 0.001 M HCl, 0.01 M HCl, and 0.1 M HCl correspond to pH 3, pH 2, and pH 1, respectively.
- a 0.01 M HCl solution simulates typical acidic conditions found in the stomach.
- a solution of 0.1 M NaCl provides a reasonable approximation of the ionic strength conditions found throughout the body, including the gastrointestinal fluids, although concentrations higher than 0.1 M may be employed to simulate fed conditions within the human GI tract.
- Exemplary solutions of salts, acids, bases or combinations thereof, which exhibit the desired pH and ionic strength include but are not limited to phosphoric acid/phosphate salts+sodium, potassium and calcium salts of chloride, acetic acid/acetate salts+sodium, potassium and calcium salts of chloride, carbonic acid/bicarbonate salts+sodium, potassium and calcium salts of chloride, and citric acid/citrate salts+sodium, potassium and calcium salts of chloride.
- the redispersed statin particles of the invention (redispersed in an aqueous, biorelevant, or any other suitable media) have an effective average particle size of less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, or less than about 50 nm, as measured by light-scattering methods, microscopy, or other
- an effective average particle size of less than about 2000 nm it is meant that at least 50% of the statin particles have a particle size less than the effective average, by weight, i.e., less than about 2000 nm, 1900 nm, 1800 nm, etc., when measured by the above-noted techniques.
- at least about 70%, about 90%, about 95%, or about 99% of the statin particles have a particle size less than the effective average, i.e., less than about 2000 nm, 1900 nm, 1800 nm, 1700 nm, etc.
- Redispersibility can be tested using any suitable means known in the art. See e.g., the example sections of U.S. Pat. No. 6,375,986 for “Solid Dose Nanoparticulate Compositions Comprising a Synergistic Combination of a Polymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate.”
- Bioadhesive statin compositions of the invention comprise at least one cationic surface stabilizer, which are described in more detail below.
- Bioadhesive formulations of statins exhibit exceptional bioadhesion to biological surfaces, such as mucous.
- the term bioadhesion refers to any attractive interaction between two biological surfaces or between a biological and a synthetic surface.
- bioadhesion is used to describe the adhesion between the nanoparticulate statin compositions and a biological substrate (i.e. gastrointestinal mucin, lung tissue, nasal mucosa, etc.). See e.g., U.S. Pat. No. 6,428,814 for “Bioadhesive Nanoparticulate Compositions Having Cationic Surface Stabilizers,” which is specifically incorporated by reference.
- bioadhesion phenomena There are basically two mechanisms which may be responsible for this bioadhesion phenomena: mechanical or physical interactions and chemical interactions.
- the first of these, mechanical or physical mechanisms involves the physical interlocking or interpenetration between a bioadhesive entity and the receptor tissue, resulting from a good wetting of the bioadhesive surface, swelling of the bioadhesive polymer, penetration of the bioadhesive entity into a crevice of the tissue surface, or interpenetration of bioadhesive composition chains with those of the mucous or other such related tissues.
- the second possible mechanism of bioadhesion incorporates forces such as ionic attraction, dipolar forces, van der Waals interactions, and hydrogen bonds.
- bioadhesion which is primarily responsible for the bioadhesive properties of the nanoparticulate statin compositions of the invention.
- physical and mechanical interactions may also play a secondary role in the bioadhesion of such nanoparticulate compositions.
- bioadhesive statin compositions of the invention are useful in any situation in which it is desirable to apply the compositions to a biological surface.
- the bioadhesive statin compositions coat the targeted surface in a continuous and uniform film which is invisible to the naked human eye.
- a bioadhesive statin composition slows the transit of the composition, and some statin particles would also most likely adhere to tissue other than the mucous cells and therefore give a prolonged exposure to the statin, thereby increasing absorption and the bioavailability of the administered dosage.
- statin compositions of the invention can additionally comprise one or more compounds useful: (1) in treating conditions such as dyslipidemia, hyperlipidemia, hypercholesterolemia, cardiovascular disorders, hypertriglyceridemia, coronary heart disease, and peripheral vascular disease (including symptomatic carotid artery disease), or related conditions; (2) as adjunctive therapy to diet for the reduction of LDL-C, total-C, triglycerides, and/or Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb); (3) as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia); (4) in treating pancreatitis; (5) in treating restenosis; and/or (6) in treating Alzheimer's disease.
- conditions such as dyslipidemia, hyperlipidemia, hypercholesterolemia, cardiovascular disorders, hypertriglyceridemia, coronary heart disease, and peripheral vascular disease (including symptomatic carotid artery disease), or related
- non-statin compositions useful in the claimed invention include, but are not limited to, cholesterol lowering agents, polycosanols, alkanoyl L-carnitines, antihypertensives, sterols and/or stanols.
- Useful cholesterol lowering agents are well known to those of skill in the art and include, but are not limited to, ACE inhibitors, nicotinic acid, niacin, bile acid sequestrants, fibrates, vitamins, fatty acid derivatives such as fish oil, long chain plant extract alcohols such as policosinol, ezetimibe, and celluloses.
- Useful polycosanols include, but are not limited to, triacontanol, hexacontanol, ecocosanol, hexacosanol, tetracosanol, dotriacontanol, tetracontanol, or natural products or extracts from natural products containing such compounds.
- Useful alkanoyl L-carnitines include, but are not limited to, acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, valeryl L-carnitine, and isovaleryl L-carnitine, or a pharmacologically acceptable salt thereof.
- antihypertensives include, but are not limited to diuretics (“water pills”), beta blockers, alpha blockers, alpha-beta blockers, sympathetic nerve inhibitors, angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, angiotensin receptor blockers (formal medical name angiotensin-2-receptor antagonists, known as “sartans” for short).
- ACE angiotensin converting enzyme
- sterols and stanols include, but are not limited to plant sterols, plant sterol esters, fish oil, sitosterol, sitostanol, phytosterol, campestanol, stigmasterol, coprostanol, cholestanol, beta-sitosterol, and the like.
- Such additional compounds can have a conventional non-nanoparticulate particle size, i.e., an effective average particle size greater than about 2 microns, or such additional compounds can be formulated into a nanoparticulate particle size, i.e., an effective average particle size of less than about 2 microns. If such one or more non-statin compounds have a nanoparticulate particle size, then preferably such non-statin compounds are poorly soluble in at least one liquid media (poorly soluble as defined in the “Definitions” section, above), and have at least one surface stabilizer adsorbed on or associated with the surface of the non-statin compound.
- the one or more surface stabilizers utilized in the composition of the non-statin compound can be the same as or different from the one or more surface stabilizers utilized in the statin composition. A description of surface stabilizers useful in the invention is provided below.
- the present invention is directed to nanoparticulate active agent compositions comprising at least one statin, such as lovastatin or simvastatin, and novel statin combinations.
- the compositions preferably comprise at least one statin and at least one surface stabilizer adsorbed on, or associated with, the surface of the statin.
- the nanoparticulate statin particles preferably have an effective average particle size of less than about 2000 nm.
- novel combinations of statins and other cholesterol lowering agents are described and methods of using the same are taught.
- the present invention also includes nanoparticulate statin compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers.
- the compositions can be formulated for various routes of administration including but not limited to, oral, rectal, ocular, and parenteral injection (e.g., intravenous, intramuscular, or subcutaneous), oral administration in solid (the preferred route), liquid, or aerosol form, vaginal, nasal, rectal, ocular, local (e.g., in powder, ointment or drop form), buccal, intracisternal, intraperitoneal, or topical administration, and the like.
- routes of administration including but not limited to, oral, rectal, ocular, and parenteral injection (e.g., intravenous, intramuscular, or subcutaneous), oral administration in solid (the preferred route), liquid, or aerosol form, vaginal, nasal, rectal, ocular, local (e.g., in powder, ointment or drop
- statin means any HMG-CoA Reductase Inhibitor (including their analogs), or a salt thereof, having preferably the solubility in water of lovastatin or simvastatin, or a solubility in water of less than about 30 mg/ml, less than about 20 mg/ml, less than about 10 mg/ml, or more preferably less than about 1 mg/ml.
- the one or more statin particles, or salt thereof can be in a crystalline phase, an amorphous phase, a semi-crystalline phase, a semi-amorphous phase, or a mixture thereof
- statin compounds include, but are not limited to, atorvastatin (Lipitor®) (U.S. Pat. No. 4,681,893) and other 6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-ones and derivatives as disclosed in U.S. Pat. No. 4,647,576); fluvastatin (Lescol®) (U.S. Pat. No. 5,354,772); lovastatin (U.S. Pat. No. 4,231,938); pravastatin (U.S. Pat. No. 4,346,227); simvastatin (U.S. Pat. No.
- Lovastatin is one of the most important known cholesterol lowering agents. Lovastatin as used herein (CAS Registry No. 75330-75-5) is also known as mevinolin or monacolin K and is chemically known as beta, beta-dihydroxy-7-[1,2,6,7,8,8 a -hexahydro-2,6-dimethyl-8-(2-methyl -butyryloxy)-1-napthalen-1-yl]-heptanoic acid beta-lactone. Lovastatin is one member of a class of compounds which are referred to generally as statins and which are known to exist in open ring hydroxy acid and in lactone form.
- Lovastatin and its analogs inhibit HMG-CoA reductase.
- Lovastatin is specifically advantageous because, as a result of its application, biosynthetic intermediates that have a toxic steroid skeleton formed at a later stage of biosynthesis fail to accumulate.
- Lovastatin also increases the number of LDL-receptors at the surface of the cell membrane, which remove the LDL cholesterol circulating in the blood, thereby inducing the lowering of blood plasma cholesterol level.
- Lovastatin is routinely produced via fermentation and is a white, nonhygroscopic crystalline powder that is insoluble in water and sparingly soluble in ethanol, methanol, and acetonitrile.
- Lovastatin tablets are commercially supplied as 10 mg, 20 mg, and 40 mg tablets for oral administration.
- each tablet contains cellulose, lactose, magnesium stearate, and starch.
- Butylated hydroxyanisole (BHA) is added as a preservative.
- Lovastatin is well known in the art and is readily recognized by one of ordinary skill. High LDL cholesterol is usually first treated with exercise, weight loss in obese individuals, and a diet low in cholesterol and saturated fats. When these measures fail, cholesterol-lowering medications such as lovastatin can be added.
- the National Cholesterol Education Program (NCEP) has published treatment guidelines for use of statins such as lovastatin. These treatment guidelines take into account the level of LDL cholesterol as well as the presence of other risk factors such as diabetes, hypertension, cigarette smoking, low HDL cholesterol level, and family history of early coronary heart disease.
- the effectiveness of the statin medications in lowering cholesterol is dose-related. Blood cholesterol determinations are performed in regular intervals during treatment so that dosage adjustments can be made. A reduction in LDL cholesterol level can be seen two weeks after starting therapy with a statin.
- Surface stabilizers especially useful herein physically adhere on or associate with the surface of the nanoparticulate statin but do not chemically react with the statin particles or itself.
- individual molecules of the surface stabilizer are essentially free of intermolecular cross-linkages.
- a surface stabilizer for a statin is non-trivial and required extensive experimentation to realize a desirable formulation for the active ingredient's therapeutic effect desired.
- the effectiveness of using of a particular stabilizer with an active ingredient is unpredictable because the stabilizer among other factors, will effect dissolution and pharmacokinetic profiles for a statin.
- the present invention is directed to the surprising discovery that stable, therapeutically useful, nanoparticulate statin compositions can be made.
- Combinations of more than one surface stabilizer can preferably be used in the invention.
- Useful surface stabilizers which can be employed in the invention include, but are not limited to, known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products, and surfactants. Preferred surface stabilizers include nonionic, anionic, cationic, and zwitterionic surfactants.
- surface stabilizers include hydroxypropylmethylcellulose (anionic), hydroxypropylcellulose, polyvinylpyrrolidone, sodium lauryl sulfate, dioctylsulfosuccinate (anionic), gelatin, casein, lecithin (phosphatides), dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens® such as e.g., Tween 20® and Tween 80® (ICI Speciality Chemicals)); polyethylene glycols (e.g.,
- useful surface stabilizers include, but are not limited to, polymers, biopolymers, polysaccharides, cellulosics, alginates, phospholipids, and nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-methylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, polylysine, polyvinylimidazole, polybrene, polymethylmethacrylate trimethylammoniumbromide bromide (PMMTMABr), hexadecyltrimethylammonium bromide (HDMAB), and polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate.
- polymers biopolymers, polysaccharides, cellulosics, alginates, phospholipids, and nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-methylpyridinium, an
- cationic stabilizers include, but are not limited to, cationic lipids, sulfonium, phosphonium, and quarternary ammonium compounds, such as stearyltrimethylammonium chloride, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride or bromide, coconut methyl dihydroxyethyl ammonium chloride or bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride or bromide, C 12-15 dimethyl hydroxyethyl ammonium chloride or bromide, coconut dimethyl hydroxyethyl ammonium chloride or bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride or bromide, lauryl dimethyl (ethenoxy) 4 ammonium chloride or bromide, N-
- Such exemplary cationic surface stabilizers and other useful cationic surface stabilizers are described in J. Cross and E. Singer, Cationic Surfactants: Analytical and Biological Evaluation (Marcel Dekker, 1994); P. and D. Rubingh (Editor), Cationic Surfactants: Physical Chemistry (Marcel Dekker, 1991); and J. Richmond, Cationic Surfactants: Organic Chemistry, (Marcel Dekker, 1990).
- Nonpolymeric surface stabilizers are any nonpolymeric compound, such benzalkonium chloride, a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quarternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound, a primary ammonium compound, a secondary ammonium compound, a tertiary ammonium compound, and quarternary ammonium compounds of the formula NR 1 R 2 R 3 R 4 .
- benzalkonium chloride a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quarternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound, a primary ammonium
- R 1 -R 4 are CH 3 , one of R 1 -R 4 is C 6 H 5 CH 2 , and one of R 1 -R 4 is an alkyl chain of nineteen carbon atoms or more;
- R 1 -R 4 two of R 1 -R 4 are CH 3 , one of R 1 -R 4 is C 6 H 5 CH 2 , and one of R 1 -R 4 comprises at least one heteroatom;
- R 1 -R 4 two of R 1 -R 4 are CH 3 , one of R 1 -R 4 is C 6 H 5 CH 2 , and one of R 1 -R 4 comprises at least one halogen;
- Such compounds include, but are not limited to, behenalkonium chloride, benzethonium chloride, cetylpyridinium chloride, behentrimonium chloride, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, cetrimonium chloride, cethylamine hydrofluoride, chlorallylmethenamine chloride (Quaternium-15), distearyldimonium chloride (Quaternium-5), dodecyl dimethyl ethylbenzyl ammonium chloride(Quaternium-14), Quaternium-22, Quaternium-26, Quaternium-18 hectorite, dimethylaminoethylchloride hydrochloride, cysteine hydrochloride, diethanolammonium POE (10) oletyl ether phosphate, diethanolammonium POE (3)oleyl ether phosphate, tallow alkonium chloride, dimethyl dioctadecylammoniumbento
- the surface stabilizers are commercially available and/or can be prepared by techniques known in the art.
- compositions according to the invention may also comprise one or more binding agents, filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and other excipients depending upon the route of administration and the dosage form desired.
- excipients are known in the art.
- filling agents are lactose monohydrate, lactose anhydrous, and various starches
- binding agents are various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose, such as Avicel® PH101 and Avicel® PH102, microcrystalline cellulose, and silicified microcrystalline cellulose (ProSolv SMCCTM).
- Suitable lubricants including agents that act on the flowability of the powder to be compressed, are colloidal silicon dioxide, such as Aerosil® 200, talc, stearic acid, magnesium stearate, calcium stearate, and silica gel.
- sweeteners are any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame.
- sweeteners are any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame.
- flavoring agents are Magnasweet® (trademark of MAFCO), bubble gum flavor, and fruit flavors, and the like.
- preservatives examples include potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quarternary compounds such as benzalkonium chloride.
- Suitable diluents include pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing.
- examples of diluents include microcrystalline cellulose, such as Avicel® PH101 and Avicel® PH102; lactose such as lactose monohydrate, lactose anhydrous, and Pharmatose® DCL21; dibasic calcium phosphate such as Emcompress®; mannitol; starch; sorbitol; sucrose; and glucose.
- Suitable disintegrants include lightly crosslinked polyvinyl pyrrolidone, corn starch, potato starch, maize starch, and modified starches, croscarmellose sodium, cross-povidone, sodium starch glycolate, and mixtures thereof
- effervescent agents are effervescent couples such as an organic acid and a carbonate or bicarbonate.
- Suitable organic acids include, for example, citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts.
- Suitable carbonates and bicarbonates include, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate.
- sodium bicarbonate component of the effervescent couple may be present.
- compositions of the invention contain statin nanoparticles, such as lovastatin or simvastatin nanoparticles, which have an effective average particle size of less than about 2000 nm (i.e., 2 microns).
- the statin nanoparticles have an effective average particle size of less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm,
- an effective average particle size of less than about 2000 nm it is meant that at least 50% of the statin particles have a particle size less than the effective average, by weight, i.e., less than about 2000 nm, about 1900 nm, about 1800 nm, etc., when measured by the above-noted techniques.
- at least about 70%, about 90%, about 95%, or about 99% of the statin particles have a particle size of less than the effective average, i.e., less than about 2000 nm, about 1900 nm, about 1800 nm, etc.
- the value for D50 of a nanoparticulate statin composition is the particle size below which 50% of the statin particles fall, by weight.
- D90 is the particle size below which 90% of the statin particles fall, by weight.
- the relative amounts of at least one statin and one or more surface stabilizers can vary widely.
- the optimal amount of the individual components depends, for example, upon one or more of the physical and chemical attributes of the particular statin selected and surface stabilizer(s) selected, such as the hydrophilic lipophilic balance (HLB), melting point, and the surface tension of water solutions of the stabilizer, etc.
- HLB hydrophilic lipophilic balance
- the concentration of the at least one statin can vary from about 99.5% to about 0.001%, preferably from about 95% to about 0.1%, preferably from about 90% to about 0.5%, by weight, based on the total combined weight of the statin and at least one surface stabilizer, not including other excipients. Higher concentrations of the active ingredient are generally preferred from a dose and cost efficiency standpoint.
- the concentration of the at least one surface stabilizer can vary from about 0.5% to about 99.999%, from about 5.0% to about 99.9%, or from about 10% to about 99.5%, by weight, based on the total combined dry weight of the statin and at least one surface stabilizer, not including other excipients.
- Exemplary useful ratios of active ingredient to stabilizers herein are preferably about 1:1, preferably about 2:1, preferably about 3:1, preferably about 4:1, preferably about 5:1, preferably about 6:1, preferably about 7:1, preferably about 8:1, and preferably about 10:1, by weight, based on the total combined dry weight of the statin and at least one surface stabilizer, not including other excipients.
- the nanoparticulate statin compositions can be made using any suitable method known in the art such as, for example, milling, homogenization, or precipitation techniques. Exemplary methods of making nanoparticulate compositions are described in the '684 patent. Methods of making nanoparticulate compositions are also described in U.S. Pat. No. 5,518,187 for “Method of Grinding Pharmaceutical Substances;” U.S. Pat. No. 5,718,388 for “Continuous Method of Grinding Pharmaceutical Substances;” U.S. Pat. No. 5,862,999 for “Method of Grinding Pharmaceutical Substances;” U.S. Pat. No.
- the resultant nanoparticulate statin compositions or dispersions can be utilized in solid or liquid dosage formulations, such as liquid dispersions, gels, aerosols, ointments, creams, controlled release formulations, fast melt formulations, lyophilized formulations, tablets, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, mixed immediate release and controlled release formulations, etc.
- Solid dose forms of the dispersions of novel statin formulations according to the present invention can be made as described in U.S. Pat. No. 6,375,986.
- Milling a statin to obtain a nanoparticulate statin dispersion comprises dispersing statin particles in a liquid dispersion medium in which the statin is poorly soluble, followed by applying mechanical means in the presence of grinding media to reduce the particle size of the statin to the desired effective average particle size.
- the dispersion medium can be, for example, water, safflower oil, ethanol, t-butanol, glycerin, polyethylene glycol (PEG), hexane, or glycol.
- the statin particles can be reduced in size preferably in the presence of at least one surface stabilizer.
- the statin particles can be contacted with one or more surface stabilizers after attrition.
- Other compounds, such as a diluent, can be added to the statin/surface stabilizer composition during the size reduction process.
- Dispersions can be manufactured continuously or in a batch mode.
- Another method of forming the desired nanoparticulate statin composition is by microprecipitation.
- This is a method of preparing stable dispersions of poorly soluble active agents in the presence of one or more surface stabilizers and one or more colloid stability enhancing surface active agents free of any trace toxic solvents or solubilized heavy metal impurities.
- Such a method comprises, for example: (1) dissolving statin in a suitable solvent; (2) adding the formulation from step (1) to a solution comprising at least one surface stabilizer; and (3) precipitating the formulation from step (2) using an appropriate non-solvent.
- the method can be followed by removal of any formed salt, if present, by dialysis or diafiltration and concentration of the dispersion by conventional means.
- Such a method comprises dispersing statin particles in a liquid dispersion media in which the statin is poorly soluble, followed by subjecting the dispersion to homogenization to reduce the particle size of the statin to the desired effective average particle size.
- the statin particles can be reduced in size in the presence of at least one surface stabilizer.
- the statin particles can be contacted with one or more surface stabilizers either before or after attrition.
- Other compounds, such as a diluent can be added to the statin/surface stabilizer composition either before, during, or after the size reduction process.
- Dispersions can be manufactured continuously or in a batch mode.
- statin compositions of the present invention can be administered to a subject via any conventional means including, but not limited to, preferably orally, rectally, ocularly, parenterally (e.g., intravenous, intramuscular, or subcutaneous), intracisternally, pulmonary, intravaginally, intraperitoneally, locally (e.g., powders, ointments or drops), or as a buccal or nasal spray.
- parenterally e.g., intravenous, intramuscular, or subcutaneous
- intracisternally e.g., intravenous, intramuscular, or subcutaneous
- pulmonary e.g., intravaginally
- intraperitoneally e.g., powders, ointments or drops
- buccal or nasal spray e.g., powders, ointments or drops
- the present invention provides a method of prolonging plasma levels of statin in a subject while achieving the desired therapeutic effect.
- a method comprises orally administering to a subject an effective amount of a composition of this invention comprising statin.
- compositions of the invention are useful in treating conditions that may be directly or indirectly associated with elevated and/or uncontrolled cholesterol metabolism as described herein and known to those in the art.
- compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
- suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- the nanoparticulate statin compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the growth of microorganisms can also be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.
- Solid dosage forms for oral administration are preferred and include, but are not limited to, capsules, tablets, pills, powders, caplets, and granules.
- the active agent i.e. the composition of this invention
- the active agent is admixed with at least one of the following: (a) one or more inert excipients (or carriers), such as sodium citrate or dicalcium phosphate; (b) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (c) binders, such as carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (d) humectants, such as glycerol; (e) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (f) solution retarders, such as paraffin; (g
- Liquid dosage forms for oral administration include pharmaceutically acceptable dispersions, emulsions, solutions, suspensions, syrups, and elixirs.
- the liquid dosage forms may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers.
- Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.
- oils such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil
- glycerol tetrahydrofurfuryl alcohol
- polyethyleneglycols fatty acid esters of sorbitan, or mixtures of these substances, and the like.
- composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- statin composition of this invention can be determined empirically and can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester, or prodrug form.
- Actual dosage levels of statin in the nanoparticulate compositions of the invention may be varied to obtain an amount of statin that is effective to obtain a desired therapeutic response for a particular composition and method of administration and the condition to be treated.
- the selected dosage level therefore depends upon the desired therapeutic effect, the route of administration, the potency of the administered statin, the desired duration of treatment, and other factors.
- Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors: the type and degree of the cellular or physiological response to be achieved; activity of the specific agent or composition employed; the specific agents or composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the agent; the duration of the treatment; drugs used in combination or coincidental with the specific agent; and like factors well known in the medical arts.
- Statin compositions of the present invention are also particularly useful when given pursuant to the method of this invention in combination with a therapeutically effective amount of at least one other active agent useful: (1) in treating conditions such as dyslipidemia, hyperlipidemia, hypercholesterolemia, cardiovascular disorders, hypertriglyceridemia, coronary heart disease, and peripheral vascular disease (including symptomatic carotid artery disease), or related conditions; (2) as adjunctive therapy to diet for the reduction of LDL-C, total-C, triglycerides, and/or Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb); (3) as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia); (4) in treating pancreatitis; (5) in treating restenosis; and/or (6) in treating Alzheimer's disease.
- active agent such as dyslipidemia, hyperlipidemia, hypercholesterolemia, cardiovascular disorders, hypertriglyceridemia,
- non-statin compositions useful in the claimed invention include, but are not limited to, cholesterol lowering agents, polycosanols, alkanoyl L-carnitines, antihypertensives, sterols and/or stanols.
- Useful cholesterol lowering agents are well known to those of skill in the art and include, but are not limited to, ACE inhibitors, nicotinic acid, niacin, bile acid sequestrants, fibrates, vitamins, fatty acid derivatives such as fish oil, long chain plant extract alcohols such as policosinol, ezetimibe, and celluloses.
- Useful polycosanols include, but are not limited to, triacontanol, hexacontanol, ecocosanol, hexacosanol, tetracosanol, dotriacontanol, tetracontanol, or natural products or extracts from natural products containing such compounds.
- Useful alkanoyl L-carnitines include, but are not limited to, acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, valeryl L-carnitine, and isovaleryl L-carnitine, or a pharmacologically acceptable salt thereof.
- antihypertensives include, but are not limited to diuretics (“water pills”), beta blockers, alpha blockers, alpha-beta blockers, sympathetic nerve inhibitors, angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, angiotensin receptor blockers (formal medical name angiotensin-2-receptor antagonists, known as “sartans” for short).
- ACE angiotensin converting enzyme
- sterols and stanols include, but are not limited to plant sterols, plant sterol esters, fish oil, sitosterol, sitostanol, phytosterol, campestanol, stigmasterol, coprostanol, cholestanol, beta-sitosterol, and the like.
- “Stanols” as used herein mean plant stanol esters, a food ingredient that can help reduce LDL cholesterol. Plant stanols are derived from naturally occurring substances in plants by techniques known to those in the art. The stanols are frequently combined with a small amount of canola oil to form stanol esters, producing an ingredient that can be used in a wide variety of foods and in combination with the compositions of this invention.
- the particle sizes were measured using a Horiba LA-910 Laser Scattering Particle Size Distribution Analyzer (Horiba Instruments, Irvine, Calif.).
- the particle mean and D 90 (which is the size below which 90% of the distribution is located) are obtained from a weight distribution. Furthermore, all formulations are given in weight % (w/w).
- the purpose of this example was to prepare nanoparticulate dispersions of lovastatin, and to test the prepared compositions for stability at varying temperatures.
- lovastatin Four formulations of lovastatin were milled, as described in Table 1, by milling the components of the compositions under high energy milling conditions in a DYNO®-Mill KDL (Willy A. Bachofen AG, Maschinenfabrik, Basle, Switzerland) for 2 to 3 hours until the desired particle size was achieved.
- Formulation 1 comprised 5% (w/w) lovastatin, 1.25% (w/w) Hydroxypropylcellulose, super-low viscosity grade (HPC-SL), and 0.05% (w/w) dioctyl sodium sulfosuccinate (DOSS).
- Formulation 2 comprised 5% (w/w) lovastatin, 1.25% (w/w) hydroxypropylmethylcellulose (HPMC), and 0.05% (w/w) dioctyl sodium sulfosuccinate (DOSS).
- Formulation 3 comprised 5% (w/w) lovastatin, 1.25% (w/w) Povidone USP, Plasdone® K29/52 (PVPK29 ⁇ 32), and 0.05% (w/w) dioctyl sodium sulfosuccinate (DOSS).
- Formulation 4 comprised 5% (w/w) lovastatin, 1.25% (w/w) Plasdone 5630 (S630), and 0.05% (w/w) dioctyl sodium sulfosuccinate (DOSS).
- the particle size of the resultant compositions was measured using a Horiba LA-910 Laser Scattering Particle Size Distribution Analyzer ((Horiba Instruments, Irvine, Calif.).
- lovastatin has a potential for oxidative degradation.
- an HPLC analysis was performed on the compositions prepared in Example 1.
- the method was a reversed phase HPLC method based on an existing assay method found in the literature ( Pharmazie, Volume 56, September 2001, p 738-740). The results of these sample runs were compared to an active pharmaceutical ingredient (API), commercially available lovastatin, standard to determine which milled sample was least oxidized.
- API active pharmaceutical ingredient
- Formulation #2 containing HPMC compared the best with the API standard. Both had similar amount of impurities, percent lovastain, and comparable peak areas at RRT 0.87.
- the sample containing PVP K29/32 had the highest amount of impurities, lowest percent lovastatin, and the largest peak area at RRT 0.87.
- the purpose of this example was to evaluate the efficacy of nanoparticulate lovastatin compositions.
- New Zealand White rabbits were fed a diet enriched with 1% cholesterol for four weeks. At the four week time point the animals were maintained on a high cholesterol diet but were dosed (in the fed state) each day for a additional four week period with 6 mg/kg dose of either suspensions of Formulation #2 (Example 1) or commercially available lovastatin (Mevacor®) tablets mortarized into a crude suspension comprising the same quantities of HPMC and DOSS as Formulation #2. Placebo also comprised the same quantities of HPMC and DOSS as formulation #2.
- Formulation #2 dosed as a liquid suspension: ⁇ 23.2% (N 8) 3.
- Placebo dosed as a liquid suspension: ⁇ 12.3 (N 4) 4.
- Diet enriched with 1% cholesterol (not dosed): +0.10 (N 4)
Abstract
Description
- The present invention relates to nanoparticulate compositions comprising statin, preferably lovastatin or simvastatin, and novel statin combinations. The nanoparticulate statin particles preferably have an effective average particle size of less than about 2000 nm. In another aspect, this invention includes novel combinations of statins and other cholesterol lowering agents and methods of using the same.
- I. Background Regarding Nanoparticulate Active Agent Compositions
- Nanoparticulate active agent compositions, first described in U.S. Pat. No. 5,145,684 (“the '684 patent”), are particles consisting of a poorly soluble therapeutic or diagnostic agent having adsorbed onto, or associated with, the surface thereof a non-crosslinked surface stabilizer. Many factors can affect bioavailability including the dosage form and various properties, e.g., dissolution rate of the drug. Poor bioavailability is a significant problem encountered in the development of pharmaceutical compositions, particularly those containing an active ingredient that is poorly soluble in water. By decreasing the particle size of an active agent, the surface area of the composition is increased, thereby generally resulting in an increased bioavailability. The '684 patent does not teach nanoparticulate compositions of statins.
- Methods of making nanoparticulate active agent compositions are described in, for example, U.S. Pat. Nos. 5,518,187 and 5,862,999, both for “Method of Grinding Pharmaceutical Substances;” U.S. Pat. No. 5,718,388, for “Continuous Method of Grinding Pharmaceutical Substances;” and U.S. Pat. No. 5,510,118 for “Process of Preparing Therapeutic Compositions Containing Nanoparticles.”
- Nanoparticulate active agent compositions are also described, for example, in U.S. Pat. No. 5,298,262 for “Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Sterilization;” No. 5,302,401 for “Method to Reduce Particle Size Growth During Lyophilization;” No. 5,318,767 for “X-Ray Contrast Compositions Useful in Medical Imaging;” 5,326,552 for “Novel Formulation For Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-ionic Surfactants;” No. 5,328,404 for “Method of X-Ray Imaging Using Iodinated Aromatic Propanedioates;” No. 5,336,507 for “Use of Charged Phospholipids to Reduce Nanoparticle Aggregation;” No. 5,340,564 for “Formulations Comprising Olin 10-G to Prevent Particle Aggregation and Increase Stability;” No. 5,346,702 for “Use of Non-Ionic Cloud Point Modifiers to Minimize Nanoparticulate Aggregation During Sterilization;” No. 5,349,957 for “Preparation and Magnetic Properties of Very Small Magnetic-Dextran Particles;” No. 5,352,459 for “Use of Purified Surface Modifiers to Prevent Particle Aggregation During Sterilization;” Nos. 5,399,363 and 5,494,683, both for “Surface Modified Anticancer Nanoparticles;” No. 5,401,492 for “Water Insoluble Non-Magnetic Manganese Particles as Magnetic Resonance Enhancement Agents;” No. 5,429,824 for “Use of Tyloxapol as a Nanoparticulate Stabilizer;” No. 5,447,710 for “Method for Making Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-ionic Surfactants;” No. 5,451,393 for “X-Ray Contrast Compositions Useful in Medical Imaging;” No. 5,466,440 for “Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents in Combination with Pharmaceutically Acceptable Clays;” No. 5,470,583 for “Method of Preparing Nanoparticle Compositions Containing Charged Phospholipids to Reduce Aggregation;” No. 5,472,683 for “Nanoparticulate Diagnostic Mixed Carbamic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;” No. 5,500,204 for “Nanoparticulate Diagnostic Dimers as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;” No. 5,518,738 for “Nanoparticulate NSAID Formulations;” No. 5,521,218 for “Nanoparticulate Iododipamide Derivatives for Use as X-Ray Contrast Agents;” No. 5,525,328 for “Nanoparticulate Diagnostic Diatrizoxy Ester X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;” No. 5,543,133 for “Process of Preparing X-Ray Contrast Compositions Containing Nanoparticles;” No. 5,552,160 for “Surface Modified NSAID Nanoparticles;” No. 5,560,931 for “Formulations of Compounds as Nanoparticulate Dispersions in Digestible Oils or Fatty Acids;” No. 5,565,188 for “Polyalkylene Block Copolymers as Surface Modifiers for Nanoparticles;” No. 5,569,448 for “Sulfated Non-ionic Block Copolymer Surfactant as Stabilizer Coatings for Nanoparticle Compositions;” No. 5,571,536 for “Formulations of Compounds as Nanoparticulate Dispersions in Digestible Oils or Fatty Acids;” No. 5,573,749 for “Nanoparticulate Diagnostic Mixed Carboxylic Anydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;” No. 5,573,750 for “Diagnostic Imaging X-Ray Contrast Agents;” No. 5,573,783 for “Redispersible Nanoparticulate Film Matrices With Protective Overcoats;” No. 5,580,579 for “Site-specific Adhesion Within the GI Tract Using Nanoparticles Stabilized by High Molecular Weight, Linear Poly(ethylene Oxide) Polymers;” No. 5,585,108 for “Formulations of Oral Gastrointestinal Therapeutic Agents in Combination with Pharmaceutically Acceptable Clays;” No. 5,587,143 for “Butylene Oxide-Ethylene Oxide Block Copolymers Surfactants as Stabilizer Coatings for Nanoparticulate Compositions;” No. 5,591,456 for “Milled Naproxen with Hydroxypropyl Cellulose as Dispersion Stabilizer;” No. 5,593,657 for “Novel Barium Salt Formulations Stabilized by Non-ionic and Anionic Stabilizers;” No. 5,622,938 for “Sugar Based Surfactant for Nanocrystals;” No. 5,628,981 for “Improved Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents and Oral Gastrointestinal Therapeutic Agents;” No. 5,643,552 for “Nanoparticulate Diagnostic Mixed Carbonic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;” No. 5,718,388 for “Continuous Method of Grinding Pharmaceutical Substances;” No. 5,718,919 for “Nanoparticles Containing the R(−)Enantiomer of Ibuprofen;” No. 5,747,001 for “Aerosols Containing Beclomethasone Nanoparticle Dispersions;” No. 5,834,025 for “Reduction of Intravenously Administered Nanoparticulate Formulation Induced Adverse Physiological Reactions;” No. 6,045,829 “Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV) Protease Inhibitors Using Cellulosic Surface Stabilizers;” No. 6,068,858 for “Methods of Making Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV) Protease Inhibitors Using Cellulosic Surface Stabilizers;” No. 6,153,225 for “Injectable Formulations of Nanoparticulate Naproxen;” No. 6,165,506 for “New Solid Dose Form of Nanoparticulate Naproxen;” No. 6,221,400 for “Methods of Treating Mammals Using Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV) Protease Inhibitors;” No. 6,264,922 for “Nebulized Aerosols Containing Nanoparticle Dispersions;” No. 6,267,989 for “Methods for Preventing Crystal Growth and Particle Aggregation in Nanoparticle Compositions;” No. 6,270,806 for “Use of PEG-Derivatized Lipids as Surface Stabilizers for Nanoparticulate Compositions;” No. 6,316,029 for “Rapidly Disintegrating Solid Oral Dosage Form,” No. 6,375,986 for “Solid Dose Nanoparticulate Compositions Comprising a Synergistic Combination of a Polymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate;” No. 6,428,814 for “Bioadhesive Nanoparticulate Compositions Having Cationic Surface Stabilizers;” No. 6,431,478 for “Small Scale Mill;” and No. 6,432,381 for “Methods for Targeting Drug Delivery to the Upper and/or Lower Gastrointestinal Tract,” all of which are specifically incorporated by reference. In addition, U.S. patent application No. 20020012675 A1, published on Jan. 31, 2002, for “Controlled Release Nanoparticulate Compositions,” describes nanoparticulate compositions, and is specifically incorporated by reference. None of these references describe nanoparticulate statin compositions.
- Amorphous small particle compositions are described, for example, in U.S. Pat. No. 4,783,484 for “Particulate Composition and Use Thereof as Antimicrobial Agent;” No. 4,826,689 for “Method for Making Uniformly Sized Particles from Water-Insoluble Organic Compounds;” No. 4,997,454 for “Method for Making Uniformly-Sized Particles From Insoluble Compounds;” No. 5,741,522 for “Ultrasmall, Non-aggregated Porous Particles of Uniform Size for Entrapping Gas Bubbles Within and Methods;” and No. 5,776,496, for “Ultrasmall Porous Particles for Enhancing Ultrasound Back Scatter.”
- II. Background Regarding Statins
- Recently, a number of new drugs collectively known as statins or vastatins have been introduced to reduce serum LDL cholesterol levels (representative examples of these drugs are detailed in The Merck Index). High LDL cholesterol levels have been shown to be an important risk factor in the development of arteriosclerosis and ischaemic heart disease. Statins have been found to lower serum LDL cholesterol levels in a dose dependent manner. Additionally, these drugs lower serum triglyceride levels, which is another risk factor for heart disease. Statins lower serum LDL cholesterol levels by competitive inhibition of 3-hydroxyl-3-methylglutaryl-Coenzyme A reductase (HMG-COA reductase), an enzyme involved in the biosynthesis of cholesterol. By binding tightly to the active site of the enzyme, statins block the reduction of HMG-CoA, a step necessary in the biosynthesis of cholesterol. This inhibition of cholesterol biosynthesis by a statin results in a decrease in the production and secretion of LDL cholesterol. In addition, the upregulation of LDL receptors, especially in the liver, leads to the removal of LDLs from the serum. Thus, by reducing the production of LDL cholesterol and by causing LDL cholesterol to be removed from the serum, statins effectively reduce overall serum LDL cholesterol levels.
- Two-thirds of the total cholesterol found in the body is of endogenous origin. The major site of cholesterol biosynthesis is in the liver. Such liver-derived cholesterol is the main cause of the development of hyper-cholesterolaemia. In contrast, cholesterol production in non-hepatic cells is needed for normal cell function. Therefore, selective inhibition of HMG-CoA reductase in the liver is an important requirement for HMG-COA reductase inhibitors. In this regard, statins typically have high oral availability and high hepatic extraction during their first pass through the liver. Statins have been associated with significant liver toxicity.
- Even though the current HMG-CoA reductase inhibitors are quite potent, a need exists for safer, and higher potency HMG-CoA reductase inhibitors. The present invention satisfies these needs.
- The present invention relates to nanoparticulate active agent compositions comprising at least one statin, such as lovastatin or simvastatin, and novel statin combinations. The compositions preferably comprise at least one statin and at least one surface stabilizer adsorbed on or associated with the surface of the one or more statin particles. The nanoparticulate statin particles preferably have an effective average particle size of less than about 2000 nm.
- Another aspect of the invention is directed to pharmaceutical compositions comprising a nanoparticulate statin composition of the invention. The pharmaceutical compositions preferably comprise at least one statin, at least one surface stabilizer, and at least one pharmaceutically acceptable carrier, as well as any desired excipients known to those in the art and formulated into the dosage form desired.
- In another aspect of this invention, novel combinations of statins and at least one other cholesterol lowering agent are described and methods of using the same are taught.
- Another aspect of the invention is directed to a nanoparticulate statin composition having improved pharmacokinetic profiles as compared to conventional microcrystalline statin formulations, such as improved Tmax, Cmax, and AUC parameters.
- One embodiment of the invention encompasses a statin composition, wherein the pharmacokinetic profile of the statin is not substantially affected by the fed or fasted state of a subject ingesting the composition, preferably as defined by C. and AUC guidelines given by the U.S. Food and Drug Administration and/or the corresponding European regulatory agency (EMEA).
- In yet another embodiment, the invention encompasses a statin composition of the invention, wherein administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state, in particular as defined by Cmax and AUC guidelines given by the U.S. Food and Drug Administration and the corresponding European regulatory agency (EMEA).
- Other embodiments of the invention include, but are not limited to, nanoparticulate statin compositions which, as compared to conventional non-nanoparticulate formulations of the same statin, preferably have one or more of the following properties: (1) smaller tablet or other solid dosage form size; (2) smaller doses of drug required to obtain the same pharmacological effect; (3) increased bioavailability; (4) an increased rate of dissolution for the nanoparticulate statin compositions; and (6) bioadhesive statin compositions.
- This invention further discloses a method of making a nanoparticulate statin composition according to the invention. Such method comprises contacting one or more statins and at least one surface stabilizer for a time and under conditions sufficient to provide a nanoparticulate statin composition. The one or more surface stabilizers can be contacted with the statin before, preferably during, or after size reduction of the statin.
- The present invention is also directed to methods of treatment using the nanoparticulate statin compositions of the invention for conditions such as hypercholesterolemia, hypertriglyceridemia, coronary heart disease, and peripheral vascular disease (including symptomatic carotid artery disease). In one aspect, the compositions of the invention can be used as adjunctive therapy to diet for the reduction of LDL-C, total-C, triglycerides, and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). In another aspect, the compositions can be used as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Markedly elevated levels of serum tryglycerides (e.g., >2000 mg/dL) may increase the risk of developing pancreatitis. Other diseases that may be directly or indirectly associated with elevated, uncontrolled cholesterol metabolism, e.g., restenosis and Alzheimer's disease, may also be treated with the compositions of this invention. Other methods of treatment using the nanoparticulate statin compositions of the present invention are know to those of skill in the art.
- Such methods comprise administering to a subject a therapeutically effective amount of a nanoparticulate statin pharmaceutical composition according to the invention.
- Both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following detailed description of the invention.
- The present invention relates to nanoparticulate active agent compositions comprising at least one statin, such as lovastatin or simvastatin, and novel statin combinations. The compositions preferably comprise at least one statin and at least one surface stabilizer adsorbed on or associated with the surface of the statin particles. The nanoparticulate statin particles preferably have an effective average particle size of less than about 2000 nm.
- As taught in the '684 patent, not every combination of surface stabilizer and active agent will result in a stable nanoparticulate composition. It was surprisingly discovered that stable nanoparticulate statin formulations can be made. Even though the current HMG-CoA reductase inhibitors are quite potent, a need exists for safer and higher potency HMG-CoA reductase inhibitors. Compositions of nanoparticulate statins decrease the amount of drug needed and the amount that escapes from the liver and this, in turn, decreases adverse side effects while providing maximum dose response. Additionally, a longer plasma half-life is believed to be associated with nanoparticulate statin compositions of the invention. Moreover, increasing the duration of effect of the HMG-CoA reductase inhibitor is expected to result in even lower serum cholesterol levels, with a further reduction in dose expected.
- In general, the rate of dissolution of a particulate drug can increase with increasing surface area, e.g., decreasing particle size. Consequently, methods of making finely divided drugs have been studied and efforts have been made to control the size and size range of drug particles in pharmaceutical compositions. However, nanoparticulate active agent formulations suitable for administration as a pharmaceutical require formulation of the active ingredient into a colloidal dispersion exhibiting the acceptable nanoparticle size range and the stability to maintain such size range and not agglomerate. Merely increasing surface area by decreasing particle size does not assure success. Further challenges include forming solid dose forms redispersible into the nanoparticle form upon administration to the patient to maintain the benefit of the nanoparticle statin over the traditional dosage form.
- Advantages of the nanoparticulate statin formulations of the invention as compared to conventional non-nanoparticulate formulations of the same statin preferably include, but are not limited to: (1) smaller tablet or other solid dosage form size; (2) smaller doses of drug required to obtain the same pharmacological effect; (3) increased bioavailability; (4) substantially similar pharmacokinetic profiles of the nanoparticulate statin compositions when administered in the fed versus the fasted state; (5) improved pharmacokinetic profiles; (6) bioequivalency of the nanoparticulate statin compositions when administered in the fed versus the fasted state; (7) an increased rate of dissolution for the nanoparticulate statin compositions; (8) bioadhesive statin compositions; and (9) the nanoparticulate statin compositions can be used in conjunction with other active agents.
- The present invention also includes nanoparticulate statin compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers. The compositions can be formulated for parenteral injection (e.g., intravenous, intramuscular, or subcutaneous), oral administration in solid, liquid, or aerosol form, vaginal, nasal, rectal, ocular, local (powders, ointments or drops), buccal, intracisternal, intraperitoneal, or topical administration, and the like.
- A preferred dosage form of the invention is a solid dosage form, although any pharmaceutically acceptable dosage form can be utilized. Exemplary solid dosage forms include, but are not limited to, tablets, capsules, sachets, lozenges, powders, pills, or granules. The solid dosage form can be, for example, a fast melt dosage form, controlled release dosage form, lyophilized dosage form, delayed release dosage form, extended release dosage form, pulsatile release dosage form, mixed immediate release and controlled release dosage form, or a combination thereof. A solid dose tablet formulation is preferred.
- The present invention is described herein using several definitions, as set forth below and throughout the application.
- “About” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which the term is used. If there are uses of the term which are not clear to persons of ordinary skill in the art given the context in which it is used, “about” will mean up to plus or minus 10% of the particular term. “Conventional” or “non-nanoparticulate active agent” shall mean an active agent which is solubilized or which has an effective average particle size of greater than about 2 microns.
- “Poorly water soluble drugs” as used herein means those having a solubility of less than about 30 mg/ml, preferably less than about 20 mg/ml, preferably less than about 10 mg/ml, or preferably less than about 1 mg/ml. Such drugs tend to be eliminated from the gastrointestinal tract before being absorbed into the circulation. Moreover, poorly water soluble drugs tend to be unsafe for intravenous administration techniques, which are used primarily in conjunction with highly water soluble drug substances.
- As used herein with reference to stable statin particles, “stable” includes, but is not limited to, one or more of the following parameters: (1) that the statin particles do not appreciably flocculate or agglomerate due to interparticle attractive forces, or otherwise significantly increase in particle size over time; (2) that the physical structure of the statin particles is not altered over time, such as by conversion from an amorphous phase to crystalline phase; (3) that the statin particles are chemically stable; and/or (4) where the statin has not been subject to a heating step at or above the melting point of the statin in the preparation of the nanoparticles of the invention.
- “Therapeutically effective amount” as used herein with respect to a drug dosage, shall mean that dosage that provides the specific pharmacological response for which the drug is administered in a significant number of subjects in need of such treatment. It is emphasized that “therapeutically effective amount,” administered to a particular subject in a particular instance will not always be effective in treating the diseases described herein, even though such dosage is deemed a ‘therapeutically effective amount’ by those skilled in the art. It is to be further understood that drug dosages are, in particular instances, measured as oral dosages, or with reference to drug levels as measured in blood.
- I. Preferred Characteristics of the Statin Compositions of the Invention
- A. Increased Bioavailability and Lower Dosages
- The statin compositions of the invention preferably exhibit increased bioavailability, at the same dose of the same statin, require smaller doses, and show longer plasma half-life as compared to prior conventional statin formulations.
- In one aspect of the invention, pharmaceutical statin compositions have enhanced bioavailability such that the statin dosage can be reduced, resulting in a decrease in toxicity associated with such statins. It has been surprisingly found in the present invention that stable compositions of nanoparticulate statins can be formed that permit therapeutic levels at desirably lower dosage.
- Greater bioavailability of the statin compositions of the invention can enable a smaller solid dosage size. This is particularly significant for patient populations such as the elderly, juvenile, and infant.
- B. Improved Pharmacokinetic Profiles
- The invention also preferably provides statin compositions having a desirable pharmacokinetic profile when administered to mammalian subjects. The desirable pharmacokinetic profile of the statin compositions preferably includes, but is not limited to: (1) that the Tmax of a statin when assayed in the plasma of a mammalian subject following administration is preferably less than the Tmax for a conventional, non-nanoparticulate form of the same statin, administered at the same dosage; (2) that the Cmax of a statin when assayed in the plasma of a mammalian subject following administration is preferably greater than the Cmax for a conventional, non-nanoparticulate form of the same statin, administered at the same dosage; and/or (3) that the AUC of a statin when assayed in the plasma of a mammalian subject following administration, is preferably greater than the AUC for a conventional, non-nanoparticulate form of the same statin, administered at the same dosage.
- The desirable pharmacokinetic profile, as used herein, is the pharmacokinetic profile measured after the initial dose of a statin. The compositions can be formulated in any way as described below and as known to those of skill in the art.
- A preferred statin composition of the invention exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same statin, administered at the same dosage, a Tmax not greater than about 90%, not greater than about 80%, not greater than about 70%, not greater than about 60%, not greater than about 50%, not greater than about 30%, not greater than about 25%, not greater than about 20%, not greater than about 15%, or not greater than about 10% of the Tmax, exhibited by the non-nanoparticulate formulation of the same statin.
- A preferred statin composition of the invention exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same statin, administered at the same dosage, a Cmax which is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% greater than the Cmax exhibited by the non-nanoparticulate formulation of the same statin.
- A preferred statin composition of the invention exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same statin, administered at the same dosage, an AUC which is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% greater than the AUC exhibited by the non-nanoparticulate formulation of the same statin.
- Any formulation giving the desired pharmacokinetic profile is suitable for administration according to the present methods. Exemplary types of formulations giving such profiles are liquid dispersions, gels, aerosols, ointments, creams, solid dose forms, etc. of a nanoparticulate statin.
- C. The Pharmacokinetic Profiles of the Statin Compositions of the Invention are not Affected by the Fed or Fasted State of the Subject Ingesting the Compositions
- The invention encompasses a statin composition wherein the pharmacokinetic profile of the statin is preferably not substantially affected by the fed or fasted state of a subject ingesting the composition, when administered to a human. This means that there is no substantial difference in the quantity of drug absorbed or the rate of drug absorption when the nanoparticulate statin compositions are administered in the fed versus the fasted state.
- The invention also encompasses a statin composition in which administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state. “Bioequivalency” is preferably established by a 90% Confidence Interval (CI) of between 0.80 and 1.25 for both Cmax and AUC under U.S. Food and Drug Administration regulatory guidelines, or a 90% CI for AUC of between 0.80 to 1.25 and a 90% CI for Cmax of between 0.70 to 1.43 under the European EMEA regulatory guidelines (Tmax is not relevant for bioequivalency determinations under USFDA and EMEA regulatory guidelines).
- In the prior art, lovastatin given under fasting conditions, has been shown to result in plasma concentrations of total inhibitors that were on average about two-thirds those found when lovastatin was administered immediately after a standard test meal. This significant difference of about 33% in absorption observed with conventional statin formulations is undesirable. The nanoparticulate statin formulations of the invention alleviate this problem, as the nanoparticulate statin formulations of the invention reduce differences in or preferably do not produce significantly different, absorption levels when administered under fed as compared to fasting conditions.
- Benefits of a dosage form which substantially eliminates the effect of food include an increase in subject convenience, thereby increasing subject compliance, as the subject does not need to ensure that they are taking a dose either with or without food. This is significant, as with poor subject compliance an increase in the medical condition for which the drug is being prescribed may be observed.
- The difference in absorption of the statin compositions of the invention, when administered in the fed versus the fasted state, preferably is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, or less than about 3%.
- D. Dissolution Profiles of the Statin Compositions of the Invention
- The statin compositions of the invention preferably have unexpectedly dramatic dissolution profiles. Rapid dissolution of an administered active agent is preferable, as faster dissolution generally leads to faster onset of action and greater bioavailability. To improve the dissolution profile and bioavailability of statins it would be useful to increase the drug's dissolution so that it could attain a level close to 100%.
- The statin compositions of the invention preferably have a dissolution profile in which within about 5 minutes at least about 20% of the composition is dissolved. In other embodiments of the invention, at least about 30% or about 40% of the statin composition is dissolved within about 5 minutes. In yet other embodiments of the invention, preferably at least about 40%, about 50%, about 60%, about 70%, or about 80% of the statin composition is dissolved within about 10 minutes. Finally, in another embodiment of the invention, preferably at least about 70%, about 80%, about 90%, or about 100% of the statin composition is dissolved within about 20 minutes.
- Dissolution is preferably measured in a medium which is discriminating. Such a dissolution medium will produce two very different dissolution curves for two products having very different dissolution profiles in gastric juices; i.e., the dissolution medium is predictive of in vivo dissolution of a composition. An exemplary dissolution medium is an aqueous medium containing the surfactant sodium lauryl sulfate at 0.025 M. Determination of the amount dissolved can be carried out by spectrophotometry. The rotating blade method (European Pharmacopoeia) can be used to measure dissolution.
- E. Redispersibility Profiles of the Statin Compositions of the Invention
- An additional feature of the statin compositions of the invention is that the compositions preferably redisperse such that the effective average particle size of the redispersed statin particles is less than about 2 microns. This is significant, as if upon administration the nanoparticulate statin compositions of the invention did not redisperse to a substantially nanoparticulate particle size, then the dosage form may lose the benefits afforded by formulating the statin into a nanoparticulate particle size.
- This is because nanoparticulate active agent compositions benefit from the small particle size of the active agent; if the active agent does not redisperse into the small particle sizes upon administration, then “clumps” or agglomerated active agent particles are formed, owing to the extremely high surface free energy of the nanoparticulate system and the thermodynamic driving force to achieve an overall reduction in free energy. With the formation of such agglomerated particles, the bioavailability of the dosage form may fall well below that observed with the liquid dispersion form of the nanoparticulate active agent.
- Moreover, the nanoparticulate statin compositions of the invention preferably exhibit dramatic redispersion of the nanoparticulate statin particles upon administration to a mammal, such as a human or animal, as demonstrated by reconstitution/redispersion in a biorelevant aqueous media such that the effective average particle size of the redispersed statin particles is less than about 2 microns. Such biorelevant aqueous media can be any aqueous media that exhibit the desired ionic strength and pH, which form the basis for the biorelevance of the media. The desired pH and ionic strength are those that are representative of physiological conditions found in the human body. Such biorelevant aqueous media can be, for example, aqueous electrolyte solutions or aqueous solutions of any salt, acid, or base, or a combination thereof, which exhibit the desired pH and ionic strength.
- Biorelevant pH is well known in the art. For example, in the stomach, the pH ranges from slightly less than 2 (but typically greater than 1) up to 4 or 5. In the small intestine the pH can range from 4 to 6, and in the colon it can range from 6 to 8. Biorelevant ionic strength is also well known in the art. Fasted state gastric fluid has an ionic strength of about 0.1M while fasted state intestinal fluid has an ionic strength of about 0.14. See e.g., Lindahl et al., “Characterization of Fluids from the Stomach and Proximal Jejunum in Men and Women,” Pharm. Res., 14 (4): 497-502 (1997).
- It is believed that the pH and ionic strength of the test solution is more critical than the specific chemical content. Accordingly, appropriate pH and ionic strength values can be obtained through numerous combinations of strong acids, strong bases, salts, single or multiple conjugate acid-base pairs (i.e., weak acids and corresponding salts of that acid), monoprotic and polyprotic electrolytes, etc.
- Representative electrolyte solutions can be, but are not limited to, HCl solutions, ranging in concentration from about 0.001 to about 0.1 M, and NaCl solutions, ranging in concentration from about 0.001 to about 0.1 M, and mixtures thereof. For example, electrolyte solutions can be, but are not limited to, about 0.1 M HCl or less, about 0.01 M HCl or less, about 0.001 M HCl or less, about 0.1 M NaCl or less, about 0.01 M NaCl or less, about 0.001 M NaCl or less, and mixtures thereof. Of these electrolyte solutions, 0.01 M HCl and/or 0.1 M NaCl, are most representative of fasted human physiological conditions, owing to the pH and ionic strength conditions of the proximal gastrointestinal tract.
- Electrolyte concentrations of 0.001 M HCl, 0.01 M HCl, and 0.1 M HCl correspond to pH 3, pH 2, and pH 1, respectively. Thus, a 0.01 M HCl solution simulates typical acidic conditions found in the stomach. A solution of 0.1 M NaCl provides a reasonable approximation of the ionic strength conditions found throughout the body, including the gastrointestinal fluids, although concentrations higher than 0.1 M may be employed to simulate fed conditions within the human GI tract.
- Exemplary solutions of salts, acids, bases or combinations thereof, which exhibit the desired pH and ionic strength, include but are not limited to phosphoric acid/phosphate salts+sodium, potassium and calcium salts of chloride, acetic acid/acetate salts+sodium, potassium and calcium salts of chloride, carbonic acid/bicarbonate salts+sodium, potassium and calcium salts of chloride, and citric acid/citrate salts+sodium, potassium and calcium salts of chloride.
- In other embodiments of the invention, the redispersed statin particles of the invention (redispersed in an aqueous, biorelevant, or any other suitable media) have an effective average particle size of less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, or less than about 50 nm, as measured by light-scattering methods, microscopy, or other appropriate methods.
- By “an effective average particle size of less than about 2000 nm” it is meant that at least 50% of the statin particles have a particle size less than the effective average, by weight, i.e., less than about 2000 nm, 1900 nm, 1800 nm, etc., when measured by the above-noted techniques. Preferably, at least about 70%, about 90%, about 95%, or about 99% of the statin particles have a particle size less than the effective average, i.e., less than about 2000 nm, 1900 nm, 1800 nm, 1700 nm, etc.
- Redispersibility can be tested using any suitable means known in the art. See e.g., the example sections of U.S. Pat. No. 6,375,986 for “Solid Dose Nanoparticulate Compositions Comprising a Synergistic Combination of a Polymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate.”
- F. Bioadhesive Statin Compositions
- Bioadhesive statin compositions of the invention comprise at least one cationic surface stabilizer, which are described in more detail below. Bioadhesive formulations of statins exhibit exceptional bioadhesion to biological surfaces, such as mucous. The term bioadhesion refers to any attractive interaction between two biological surfaces or between a biological and a synthetic surface. In the case of bioadhesive nanoparticulate statin compositions, the term bioadhesion is used to describe the adhesion between the nanoparticulate statin compositions and a biological substrate (i.e. gastrointestinal mucin, lung tissue, nasal mucosa, etc.). See e.g., U.S. Pat. No. 6,428,814 for “Bioadhesive Nanoparticulate Compositions Having Cationic Surface Stabilizers,” which is specifically incorporated by reference.
- There are basically two mechanisms which may be responsible for this bioadhesion phenomena: mechanical or physical interactions and chemical interactions. The first of these, mechanical or physical mechanisms, involves the physical interlocking or interpenetration between a bioadhesive entity and the receptor tissue, resulting from a good wetting of the bioadhesive surface, swelling of the bioadhesive polymer, penetration of the bioadhesive entity into a crevice of the tissue surface, or interpenetration of bioadhesive composition chains with those of the mucous or other such related tissues. The second possible mechanism of bioadhesion incorporates forces such as ionic attraction, dipolar forces, van der Waals interactions, and hydrogen bonds. It is this form of bioadhesion which is primarily responsible for the bioadhesive properties of the nanoparticulate statin compositions of the invention. However, physical and mechanical interactions may also play a secondary role in the bioadhesion of such nanoparticulate compositions.
- The bioadhesive statin compositions of the invention are useful in any situation in which it is desirable to apply the compositions to a biological surface. The bioadhesive statin compositions coat the targeted surface in a continuous and uniform film which is invisible to the naked human eye.
- A bioadhesive statin composition slows the transit of the composition, and some statin particles would also most likely adhere to tissue other than the mucous cells and therefore give a prolonged exposure to the statin, thereby increasing absorption and the bioavailability of the administered dosage.
- G. Statin Compositions Used in Conjunction with Other Active Agents
- The statin compositions of the invention can additionally comprise one or more compounds useful: (1) in treating conditions such as dyslipidemia, hyperlipidemia, hypercholesterolemia, cardiovascular disorders, hypertriglyceridemia, coronary heart disease, and peripheral vascular disease (including symptomatic carotid artery disease), or related conditions; (2) as adjunctive therapy to diet for the reduction of LDL-C, total-C, triglycerides, and/or Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb); (3) as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia); (4) in treating pancreatitis; (5) in treating restenosis; and/or (6) in treating Alzheimer's disease.
- Exemplary non-statin compositions useful in the claimed invention include, but are not limited to, cholesterol lowering agents, polycosanols, alkanoyl L-carnitines, antihypertensives, sterols and/or stanols.
- Useful cholesterol lowering agents are well known to those of skill in the art and include, but are not limited to, ACE inhibitors, nicotinic acid, niacin, bile acid sequestrants, fibrates, vitamins, fatty acid derivatives such as fish oil, long chain plant extract alcohols such as policosinol, ezetimibe, and celluloses.
- Useful polycosanols include, but are not limited to, triacontanol, hexacontanol, ecocosanol, hexacosanol, tetracosanol, dotriacontanol, tetracontanol, or natural products or extracts from natural products containing such compounds.
- Useful alkanoyl L-carnitines include, but are not limited to, acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, valeryl L-carnitine, and isovaleryl L-carnitine, or a pharmacologically acceptable salt thereof.
- Examples of antihypertensives include, but are not limited to diuretics (“water pills”), beta blockers, alpha blockers, alpha-beta blockers, sympathetic nerve inhibitors, angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, angiotensin receptor blockers (formal medical name angiotensin-2-receptor antagonists, known as “sartans” for short).
- Examples of sterols and stanols include, but are not limited to plant sterols, plant sterol esters, fish oil, sitosterol, sitostanol, phytosterol, campestanol, stigmasterol, coprostanol, cholestanol, beta-sitosterol, and the like.
- Such additional compounds can have a conventional non-nanoparticulate particle size, i.e., an effective average particle size greater than about 2 microns, or such additional compounds can be formulated into a nanoparticulate particle size, i.e., an effective average particle size of less than about 2 microns. If such one or more non-statin compounds have a nanoparticulate particle size, then preferably such non-statin compounds are poorly soluble in at least one liquid media (poorly soluble as defined in the “Definitions” section, above), and have at least one surface stabilizer adsorbed on or associated with the surface of the non-statin compound. The one or more surface stabilizers utilized in the composition of the non-statin compound can be the same as or different from the one or more surface stabilizers utilized in the statin composition. A description of surface stabilizers useful in the invention is provided below.
- II. Compositions
- The present invention is directed to nanoparticulate active agent compositions comprising at least one statin, such as lovastatin or simvastatin, and novel statin combinations. The compositions preferably comprise at least one statin and at least one surface stabilizer adsorbed on, or associated with, the surface of the statin. The nanoparticulate statin particles preferably have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of statins and other cholesterol lowering agents are described and methods of using the same are taught.
- The present invention also includes nanoparticulate statin compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers. The compositions can be formulated for various routes of administration including but not limited to, oral, rectal, ocular, and parenteral injection (e.g., intravenous, intramuscular, or subcutaneous), oral administration in solid (the preferred route), liquid, or aerosol form, vaginal, nasal, rectal, ocular, local (e.g., in powder, ointment or drop form), buccal, intracisternal, intraperitoneal, or topical administration, and the like.
- A. Statin Particles
- As used herein “statin” means any HMG-CoA Reductase Inhibitor (including their analogs), or a salt thereof, having preferably the solubility in water of lovastatin or simvastatin, or a solubility in water of less than about 30 mg/ml, less than about 20 mg/ml, less than about 10 mg/ml, or more preferably less than about 1 mg/ml.
- The one or more statin particles, or salt thereof, can be in a crystalline phase, an amorphous phase, a semi-crystalline phase, a semi-amorphous phase, or a mixture thereof
- Such statin compounds include, but are not limited to, atorvastatin (Lipitor®) (U.S. Pat. No. 4,681,893) and other 6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-ones and derivatives as disclosed in U.S. Pat. No. 4,647,576); fluvastatin (Lescol®) (U.S. Pat. No. 5,354,772); lovastatin (U.S. Pat. No. 4,231,938); pravastatin (U.S. Pat. No. 4,346,227); simvastatin (U.S. Pat. No. 4,444,784); velostatin; fluindostatin (Sandoz XU-62-320); pyrazole analogs of mevalonolactone derivatives, as disclosed in PCT application WO 86/03488; rivastatin and other pyridyldihydroxyheptenoic acids, as disclosed in European Patent 491226A; Searle's SC-45355 (a 3-substituted pentanedioic acid derivative); dichloroacetate; imidazole analogs of mevalonolactone, as disclosed in PCT application WO 86/07054; 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives, as disclosed in French Patent No. 2,596,393; 2,3-di-substituted pyrrole, furan, and thiophene derivatives, as disclosed in European Patent Application No. 0221025; naphthyl analogs of mevalonolactone, as disclosed in U.S. Pat. No. 4,686,237; octahydronaphthalenes, such as those disclosed in U.S. Pat. No. 4,499,289; keto analogs of mevinolin (lovastatin), as disclosed in European Patent Application No. 0,142,146 A2; phosphinic acid compounds; as well as other HMG CoA reductase inhibitors.
- Lovastatin is one of the most important known cholesterol lowering agents. Lovastatin as used herein (CAS Registry No. 75330-75-5) is also known as mevinolin or monacolin K and is chemically known as beta, beta-dihydroxy-7-[1,2,6,7,8,8a-hexahydro-2,6-dimethyl-8-(2-methyl -butyryloxy)-1-napthalen-1-yl]-heptanoic acid beta-lactone. Lovastatin is one member of a class of compounds which are referred to generally as statins and which are known to exist in open ring hydroxy acid and in lactone form.
- Lovastatin and its analogs inhibit HMG-CoA reductase. Lovastatin is specifically advantageous because, as a result of its application, biosynthetic intermediates that have a toxic steroid skeleton formed at a later stage of biosynthesis fail to accumulate. Lovastatin also increases the number of LDL-receptors at the surface of the cell membrane, which remove the LDL cholesterol circulating in the blood, thereby inducing the lowering of blood plasma cholesterol level.
- Lovastatin is routinely produced via fermentation and is a white, nonhygroscopic crystalline powder that is insoluble in water and sparingly soluble in ethanol, methanol, and acetonitrile.
- Lovastatin tablets are commercially supplied as 10 mg, 20 mg, and 40 mg tablets for oral administration. In addition to the active ingredient lovastatin, each tablet contains cellulose, lactose, magnesium stearate, and starch. Butylated hydroxyanisole (BHA) is added as a preservative.
- Lovastatin is well known in the art and is readily recognized by one of ordinary skill. High LDL cholesterol is usually first treated with exercise, weight loss in obese individuals, and a diet low in cholesterol and saturated fats. When these measures fail, cholesterol-lowering medications such as lovastatin can be added. The National Cholesterol Education Program (NCEP) has published treatment guidelines for use of statins such as lovastatin. These treatment guidelines take into account the level of LDL cholesterol as well as the presence of other risk factors such as diabetes, hypertension, cigarette smoking, low HDL cholesterol level, and family history of early coronary heart disease. The effectiveness of the statin medications in lowering cholesterol is dose-related. Blood cholesterol determinations are performed in regular intervals during treatment so that dosage adjustments can be made. A reduction in LDL cholesterol level can be seen two weeks after starting therapy with a statin.
- B. Surface Stabilizers
- Surface stabilizers especially useful herein physically adhere on or associate with the surface of the nanoparticulate statin but do not chemically react with the statin particles or itself. Preferably, individual molecules of the surface stabilizer are essentially free of intermolecular cross-linkages.
- The choice of a surface stabilizer for a statin is non-trivial and required extensive experimentation to realize a desirable formulation for the active ingredient's therapeutic effect desired. For example, the effectiveness of using of a particular stabilizer with an active ingredient is unpredictable because the stabilizer among other factors, will effect dissolution and pharmacokinetic profiles for a statin. Accordingly, the present invention is directed to the surprising discovery that stable, therapeutically useful, nanoparticulate statin compositions can be made.
- Combinations of more than one surface stabilizer can preferably be used in the invention. Useful surface stabilizers which can be employed in the invention include, but are not limited to, known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products, and surfactants. Preferred surface stabilizers include nonionic, anionic, cationic, and zwitterionic surfactants.
- Representative examples of surface stabilizers include hydroxypropylmethylcellulose (anionic), hydroxypropylcellulose, polyvinylpyrrolidone, sodium lauryl sulfate, dioctylsulfosuccinate (anionic), gelatin, casein, lecithin (phosphatides), dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens® such as e.g., Tween 20® and Tween 80® (ICI Speciality Chemicals)); polyethylene glycols (e.g., Carbowaxs 3550® and 934® (Union Carbide)), polyoxyethylene stearates, colloidal silicon dioxide, phosphates, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methyl cellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose phthalate, noncrystalline cellulose, magnesium aluminium silicate, triethanolamine, polyvinyl alcohol (PVA), 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol, superione, and triton), poloxamers (e.g., Pluronics F68® and F108®, which are block copolymers of ethylene oxide and propylene oxide); poloxamines (e.g., Tetronic 908®, also known as Poloxamine 908®, which is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine (BASF Wyandotte Corporation, Parsippany, N.J.)); Tetronic 1508® (T-1508) (BASF Wyandotte Corporation), Triton X-200®, which is an alkyl aryl polyether sulfonate (Dow Chemical); Crodestas F-110®, which is a mixture of sucrose stearate and sucrose distearate (Croda Inc.); p-isononylphenoxypoly-(glycidol), also known as Olin-10G® or Surfactant 10-G® (Olin Chemicals, Stamford, Conn.); Crodestas SL-40® (Croda, Inc.); and SA9OHCO, which is C18H37CH2(CON(CH3)—CH2(CHOH)4(CH2OH)2 (Eastman Kodak Co.); decanoyl-N-methylglucamide; n-decyl β-D-glucopyranoside; n-decyl β-D-maltopyranoside; n-dodecyl β-D-glucopyranoside; n-dodecyl β-D-maltoside; heptanoyl-N-methylglucamide; n-heptyl-β-D-glucopyranoside; n-heptyl β-D-thioglucoside; n-hexyl β-D-glucopyranoside; nonanoyl-N-methylglucamide; n-noyl β-D-glucopyranoside; octanoyl-N-methylglucamide; n-octyl-β-D-glucopyranoside; octyl β-D-thioglucopyranoside; PEG-derivatized phospholipid, PEG- derivatized cholesterol, PEG-derivatized cholesterol derivative, PEG- derivatized vitamin A, PEG- derivatized vitamin E, lysozyme, random copolymers of vinyl pyrrolidone and vinyl acetate, and the like such as Plasdone® S630 in a 60:40 ratio of the pyrrolidone and vinyl acetate.
- More examples of useful surface stabilizers include, but are not limited to, polymers, biopolymers, polysaccharides, cellulosics, alginates, phospholipids, and nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-methylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, polylysine, polyvinylimidazole, polybrene, polymethylmethacrylate trimethylammoniumbromide bromide (PMMTMABr), hexadecyltrimethylammonium bromide (HDMAB), and polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate.
- Other useful cationic stabilizers include, but are not limited to, cationic lipids, sulfonium, phosphonium, and quarternary ammonium compounds, such as stearyltrimethylammonium chloride, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride or bromide, coconut methyl dihydroxyethyl ammonium chloride or bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride or bromide, C12-15dimethyl hydroxyethyl ammonium chloride or bromide, coconut dimethyl hydroxyethyl ammonium chloride or bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride or bromide, lauryl dimethyl (ethenoxy)4 ammonium chloride or bromide, N-alkyl (C12-18)dimethylbenzyl ammonium chloride, N-alkyl (C14-18)dimethyl-benzyl ammonium chloride, N-tetradecylidmethylbenzyl ammonium chloride monohydrate, dimethyl didecyl ammonium chloride, N-alkyl and (C12-14) dimethyl 1-napthylmethyl ammonium chloride, trimethylammonium halide, alkyl-trimethylammonium salts and dialkyl-dimethylammonium salts, lauryl trimethyl ammonium chloride, ethoxylated alkyamidoalkyldialkylammonium salt and/or an ethoxylated trialkyl ammonium salt, dialkylbenzene dialkylammonium chloride, N-didecyldimethyl ammonium chloride, N-tetradecyldimethylbenzyl ammonium, chloride monohydrate, N-alkyl(C12-14) dimethyl 1-naphthylmethyl ammonium chloride and dodecyldimethylbenzyl ammonium chloride, dialkyl benzenealkyl ammonium chloride, lauryl trimethyl ammonium chloride, alkylbenzyl methyl ammonium chloride, alkyl benzyl dimethyl ammonium bromide, C12, C15, C17 trimethyl ammonium bromides, dodecylbenzyl triethyl ammonium chloride, poly-diallyldimethylammonium chloride (DADMAC), dimethyl ammonium chlorides, alkyldimethylammonium halogenides, tricetyl methyl ammonium chloride, decyltrimethylammonium bromide, dodecyltriethylammonium bromide, tetradecyltrimethylammonium bromide, methyl trioctylammonium chloride (ALIQUAT 336™), POLYQUAT 10™, tetrabutylammonium bromide, benzyl trimethylammonium bromide, choline esters (such as choline esters of fatty acids), benzalkonium chloride, stearalkonium chloride compounds (such as stearyltrimonium chloride and Di-stearyldimonium chloride), cetyl pyridinium bromide or chloride, halide salts of quaternized polyoxyethylalkylamines, MIRAPOL™ and ALKAQUAT™ (Alkaril Chemical Company), alkyl pyridinium salts; amines, such as alkylamines, dialkylamines, alkanolamines, polyethylenepolyamines, N,N-dialkylaminoalkyl acrylates, and vinyl pyridine, amine salts, such as lauryl amine acetate, stearyl amine acetate, alkylpyridinium salt, and alkylimidazolium salt, and amine oxides; imide azolinium salts; protonated quaternary acrylamides; methylated quaternary polymers, such as poly[diallyl dimethylammonium chloride] and poly-[N-methyl vinyl pyridinium chloride]; and cationic guar.
- Such exemplary cationic surface stabilizers and other useful cationic surface stabilizers are described in J. Cross and E. Singer, Cationic Surfactants: Analytical and Biological Evaluation (Marcel Dekker, 1994); P. and D. Rubingh (Editor), Cationic Surfactants: Physical Chemistry (Marcel Dekker, 1991); and J. Richmond, Cationic Surfactants: Organic Chemistry, (Marcel Dekker, 1990).
- Nonpolymeric surface stabilizers are any nonpolymeric compound, such benzalkonium chloride, a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quarternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound, a primary ammonium compound, a secondary ammonium compound, a tertiary ammonium compound, and quarternary ammonium compounds of the formula NR1R2R3R4. For compounds of the formula NR1R2R3R4(+):
- (i) none of R1-R4 are CH3;
- (ii) one of R1-R4 is CH3;
- (iii) three of R1-R4 are CH3;
- (iv) all of R1-R4 are CH3;
- (v) two of R1-R4 are CH3, one of R1-R4 is C6H5CH2, and one of R1-R4 is an alkyl chain of seven carbon atoms or less;
- (vi) two of R1-R4 are CH3, one of R1-R4 is C6H5CH2, and one of R1-R4 is an alkyl chain of nineteen carbon atoms or more;
- (vii) two of R1-R4 are CH3 and one of R1-R4 is the group C6H5(CH2)n, where n>1;
- (viii) two of R1-R4 are CH3, one of R1-R4 is C6H5CH2, and one of R1-R4 comprises at least one heteroatom;
- (ix) two of R1-R4 are CH3, one of R1-R4 is C6H5CH2, and one of R1-R4 comprises at least one halogen;
- (x) two of R1-R4 are CH3, one of R1-R4 is C6H5CH2, and one of R1-R4 comprises at least one cyclic fragment;
- (xi) two of R1-R4 are CH3 and one of R1-R4 is a phenyl ring; or
- (xii) two of R1-R4 are CH3 and two of R1-R4 are purely aliphatic fragments.
- Such compounds include, but are not limited to, behenalkonium chloride, benzethonium chloride, cetylpyridinium chloride, behentrimonium chloride, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, cetrimonium chloride, cethylamine hydrofluoride, chlorallylmethenamine chloride (Quaternium-15), distearyldimonium chloride (Quaternium-5), dodecyl dimethyl ethylbenzyl ammonium chloride(Quaternium-14), Quaternium-22, Quaternium-26, Quaternium-18 hectorite, dimethylaminoethylchloride hydrochloride, cysteine hydrochloride, diethanolammonium POE (10) oletyl ether phosphate, diethanolammonium POE (3)oleyl ether phosphate, tallow alkonium chloride, dimethyl dioctadecylammoniumbentonite, stearalkonium chloride, domiphen bromide, denatonium benzoate, myristalkonium chloride, laurtrimonium chloride, ethylenediamine dihydrochloride, guanidine hydrochloride, pyridoxine HCl, iofetamine hydrochloride, meglumine hydrochloride, methylbenzethonium chloride, myrtrimonium bromide, oleyltrimonium chloride, polyquaternium-1, procainehydrochloride, cocobetaine, stearalkonium bentonite, stearalkoniumhectonite, stearyl trihydroxyethyl propylenediamine dihydrofluoride, tallowtrimonium chloride, and hexadecyltrimethyl ammonium bromide.
- Most of these surface stabilizers are known pharmaceutical excipients and are described in detail in the Handbook of Pharmaceutical Excipients, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain (The Pharmaceutical Press, 2000), specifically incorporated by reference.
- The surface stabilizers are commercially available and/or can be prepared by techniques known in the art.
- C. Other Pharmaceutical Excipients
- Pharmaceutical compositions according to the invention may also comprise one or more binding agents, filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and other excipients depending upon the route of administration and the dosage form desired. Such excipients are known in the art.
- Examples of filling agents are lactose monohydrate, lactose anhydrous, and various starches; examples of binding agents are various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose, such as Avicel® PH101 and Avicel® PH102, microcrystalline cellulose, and silicified microcrystalline cellulose (ProSolv SMCC™).
- Suitable lubricants, including agents that act on the flowability of the powder to be compressed, are colloidal silicon dioxide, such as Aerosil® 200, talc, stearic acid, magnesium stearate, calcium stearate, and silica gel.
- Examples of sweeteners are any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame. Examples of flavoring agents are Magnasweet® (trademark of MAFCO), bubble gum flavor, and fruit flavors, and the like.
- Examples of preservatives are potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quarternary compounds such as benzalkonium chloride.
- Suitable diluents include pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing. Examples of diluents include microcrystalline cellulose, such as Avicel® PH101 and Avicel® PH102; lactose such as lactose monohydrate, lactose anhydrous, and Pharmatose® DCL21; dibasic calcium phosphate such as Emcompress®; mannitol; starch; sorbitol; sucrose; and glucose.
- Suitable disintegrants include lightly crosslinked polyvinyl pyrrolidone, corn starch, potato starch, maize starch, and modified starches, croscarmellose sodium, cross-povidone, sodium starch glycolate, and mixtures thereof
- Examples of effervescent agents are effervescent couples such as an organic acid and a carbonate or bicarbonate. Suitable organic acids include, for example, citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts. Suitable carbonates and bicarbonates include, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate. Alternatively, only the sodium bicarbonate component of the effervescent couple may be present.
- D. Nanoparticulate Statin Particle Size
- The compositions of the invention contain statin nanoparticles, such as lovastatin or simvastatin nanoparticles, which have an effective average particle size of less than about 2000 nm (i.e., 2 microns). In a preferred embodiment of the invention, the statin nanoparticles have an effective average particle size of less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, or less than about 50 nm, as measured by light-scattering methods, microscopy, or other appropriate methods.
- By “an effective average particle size of less than about 2000 nm” it is meant that at least 50% of the statin particles have a particle size less than the effective average, by weight, i.e., less than about 2000 nm, about 1900 nm, about 1800 nm, etc., when measured by the above-noted techniques. Preferably, at least about 70%, about 90%, about 95%, or about 99% of the statin particles have a particle size of less than the effective average, i.e., less than about 2000 nm, about 1900 nm, about 1800 nm, etc.
- In the present invention, the value for D50 of a nanoparticulate statin composition is the particle size below which 50% of the statin particles fall, by weight. Similarly, D90 is the particle size below which 90% of the statin particles fall, by weight.
- E. Concentration of Nanoparticulate Statin and Surface Stabilizers
- The relative amounts of at least one statin and one or more surface stabilizers can vary widely. The optimal amount of the individual components depends, for example, upon one or more of the physical and chemical attributes of the particular statin selected and surface stabilizer(s) selected, such as the hydrophilic lipophilic balance (HLB), melting point, and the surface tension of water solutions of the stabilizer, etc.
- Preferably, the concentration of the at least one statin can vary from about 99.5% to about 0.001%, preferably from about 95% to about 0.1%, preferably from about 90% to about 0.5%, by weight, based on the total combined weight of the statin and at least one surface stabilizer, not including other excipients. Higher concentrations of the active ingredient are generally preferred from a dose and cost efficiency standpoint.
- Preferably, the concentration of the at least one surface stabilizer can vary from about 0.5% to about 99.999%, from about 5.0% to about 99.9%, or from about 10% to about 99.5%, by weight, based on the total combined dry weight of the statin and at least one surface stabilizer, not including other excipients.
- Exemplary useful ratios of active ingredient to stabilizers herein are preferably about 1:1, preferably about 2:1, preferably about 3:1, preferably about 4:1, preferably about 5:1, preferably about 6:1, preferably about 7:1, preferably about 8:1, and preferably about 10:1, by weight, based on the total combined dry weight of the statin and at least one surface stabilizer, not including other excipients.
- III. Methods of Making Nanoparticulate Statin Compositions
- The nanoparticulate statin compositions can be made using any suitable method known in the art such as, for example, milling, homogenization, or precipitation techniques. Exemplary methods of making nanoparticulate compositions are described in the '684 patent. Methods of making nanoparticulate compositions are also described in U.S. Pat. No. 5,518,187 for “Method of Grinding Pharmaceutical Substances;” U.S. Pat. No. 5,718,388 for “Continuous Method of Grinding Pharmaceutical Substances;” U.S. Pat. No. 5,862,999 for “Method of Grinding Pharmaceutical Substances;” U.S. Pat. No. 5,665,331 for “Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents with Crystal Growth Modifiers;” U.S. Pat. No. 5,662,883 for “Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents with Crystal Growth Modifiers;” U.S. Pat. No. 5,560,932 for “Microprecipitation of Nanoparticulate Pharmaceutical Agents;” U.S. Pat. No. 5,543,133 for “Process of Preparing X-Ray Contrast Compositions Containing Nanoparticles;” U.S. Pat. No. 5,534,270 for “Method of Preparing Stable Drug Nanoparticles;” U.S. Pat. No. 5,510,118 for “Process of Preparing Therapeutic Compositions Containing Nanoparticles;” and U.S. Pat. No. 5,470,583 for “Method of Preparing Nanoparticle Compositions Containing Charged Phospholipids to Reduce Aggregation,” all of which are specifically incorporated by reference.
- The resultant nanoparticulate statin compositions or dispersions can be utilized in solid or liquid dosage formulations, such as liquid dispersions, gels, aerosols, ointments, creams, controlled release formulations, fast melt formulations, lyophilized formulations, tablets, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, mixed immediate release and controlled release formulations, etc. Solid dose forms of the dispersions of novel statin formulations according to the present invention can be made as described in U.S. Pat. No. 6,375,986.
- A. Milling to Obtain Nanoparticulate Statin Dispersions
- Milling a statin to obtain a nanoparticulate statin dispersion comprises dispersing statin particles in a liquid dispersion medium in which the statin is poorly soluble, followed by applying mechanical means in the presence of grinding media to reduce the particle size of the statin to the desired effective average particle size. The dispersion medium can be, for example, water, safflower oil, ethanol, t-butanol, glycerin, polyethylene glycol (PEG), hexane, or glycol.
- The statin particles can be reduced in size preferably in the presence of at least one surface stabilizer. Alternatively, the statin particles can be contacted with one or more surface stabilizers after attrition. Other compounds, such as a diluent, can be added to the statin/surface stabilizer composition during the size reduction process. Dispersions can be manufactured continuously or in a batch mode.
- B. Precipitation to Obtain Nanoparticulate Statin Compositions
- Another method of forming the desired nanoparticulate statin composition is by microprecipitation. This is a method of preparing stable dispersions of poorly soluble active agents in the presence of one or more surface stabilizers and one or more colloid stability enhancing surface active agents free of any trace toxic solvents or solubilized heavy metal impurities. Such a method comprises, for example: (1) dissolving statin in a suitable solvent; (2) adding the formulation from step (1) to a solution comprising at least one surface stabilizer; and (3) precipitating the formulation from step (2) using an appropriate non-solvent. The method can be followed by removal of any formed salt, if present, by dialysis or diafiltration and concentration of the dispersion by conventional means.
- C. Homogenization to Obtain Statin Nanoparticulate Compositions
- Exemplary homogenization methods of preparing active agent nanoparticulate compositions are described in U.S. Pat. No. 5,510,118, for “Process of Preparing Therapeutic Compositions Containing Nanoparticles.” Such a method comprises dispersing statin particles in a liquid dispersion media in which the statin is poorly soluble, followed by subjecting the dispersion to homogenization to reduce the particle size of the statin to the desired effective average particle size. The statin particles can be reduced in size in the presence of at least one surface stabilizer. Alternatively, the statin particles can be contacted with one or more surface stabilizers either before or after attrition. Other compounds, such as a diluent, can be added to the statin/surface stabilizer composition either before, during, or after the size reduction process. Dispersions can be manufactured continuously or in a batch mode.
- IV. Methods of Using Statin Formulations of the Current Invention
- The statin compositions of the present invention can be administered to a subject via any conventional means including, but not limited to, preferably orally, rectally, ocularly, parenterally (e.g., intravenous, intramuscular, or subcutaneous), intracisternally, pulmonary, intravaginally, intraperitoneally, locally (e.g., powders, ointments or drops), or as a buccal or nasal spray. As used herein, the term “subject” is used to mean an animal, preferably a mammal, including a human or non-human. The terms patient and subject may be used interchangeably.
- The present invention provides a method of prolonging plasma levels of statin in a subject while achieving the desired therapeutic effect. In one aspect, such a method comprises orally administering to a subject an effective amount of a composition of this invention comprising statin.
- In one aspect, the compositions of the invention are useful in treating conditions that may be directly or indirectly associated with elevated and/or uncontrolled cholesterol metabolism as described herein and known to those in the art.
- Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- The nanoparticulate statin compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the growth of microorganisms can also be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.
- Solid dosage forms for oral administration are preferred and include, but are not limited to, capsules, tablets, pills, powders, caplets, and granules. In such solid dosage forms, the active agent (i.e. the composition of this invention) is admixed with at least one of the following: (a) one or more inert excipients (or carriers), such as sodium citrate or dicalcium phosphate; (b) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (c) binders, such as carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (d) humectants, such as glycerol; (e) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (f) solution retarders, such as paraffin; (g) absorption accelerators, such as quaternary ammonium compounds; (h) wetting agents, such as cetyl alcohol and glycerol monostearate; (i) adsorbents, such as kaolin and bentonite; and (j) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof For capsules, tablets, and pills, the dosage forms may also comprise buffering agents.
- Liquid dosage forms for oral administration include pharmaceutically acceptable dispersions, emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active agent, the liquid dosage forms may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers. Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.
- Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- The effective amounts of the statin composition of this invention can be determined empirically and can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester, or prodrug form. Actual dosage levels of statin in the nanoparticulate compositions of the invention may be varied to obtain an amount of statin that is effective to obtain a desired therapeutic response for a particular composition and method of administration and the condition to be treated. The selected dosage level therefore depends upon the desired therapeutic effect, the route of administration, the potency of the administered statin, the desired duration of treatment, and other factors.
- Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors: the type and degree of the cellular or physiological response to be achieved; activity of the specific agent or composition employed; the specific agents or composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the agent; the duration of the treatment; drugs used in combination or coincidental with the specific agent; and like factors well known in the medical arts.
- V. Statin Combinations
- Statin compositions of the present invention are also particularly useful when given pursuant to the method of this invention in combination with a therapeutically effective amount of at least one other active agent useful: (1) in treating conditions such as dyslipidemia, hyperlipidemia, hypercholesterolemia, cardiovascular disorders, hypertriglyceridemia, coronary heart disease, and peripheral vascular disease (including symptomatic carotid artery disease), or related conditions; (2) as adjunctive therapy to diet for the reduction of LDL-C, total-C, triglycerides, and/or Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb); (3) as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia); (4) in treating pancreatitis; (5) in treating restenosis; and/or (6) in treating Alzheimer's disease.
- Exemplary non-statin compositions useful in the claimed invention include, but are not limited to, cholesterol lowering agents, polycosanols, alkanoyl L-carnitines, antihypertensives, sterols and/or stanols.
- Useful cholesterol lowering agents are well known to those of skill in the art and include, but are not limited to, ACE inhibitors, nicotinic acid, niacin, bile acid sequestrants, fibrates, vitamins, fatty acid derivatives such as fish oil, long chain plant extract alcohols such as policosinol, ezetimibe, and celluloses.
- Useful polycosanols include, but are not limited to, triacontanol, hexacontanol, ecocosanol, hexacosanol, tetracosanol, dotriacontanol, tetracontanol, or natural products or extracts from natural products containing such compounds.
- Useful alkanoyl L-carnitines include, but are not limited to, acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, valeryl L-carnitine, and isovaleryl L-carnitine, or a pharmacologically acceptable salt thereof.
- Examples of antihypertensives include, but are not limited to diuretics (“water pills”), beta blockers, alpha blockers, alpha-beta blockers, sympathetic nerve inhibitors, angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, angiotensin receptor blockers (formal medical name angiotensin-2-receptor antagonists, known as “sartans” for short).
- Examples of sterols and stanols include, but are not limited to plant sterols, plant sterol esters, fish oil, sitosterol, sitostanol, phytosterol, campestanol, stigmasterol, coprostanol, cholestanol, beta-sitosterol, and the like.
- “Stanols” as used herein mean plant stanol esters, a food ingredient that can help reduce LDL cholesterol. Plant stanols are derived from naturally occurring substances in plants by techniques known to those in the art. The stanols are frequently combined with a small amount of canola oil to form stanol esters, producing an ingredient that can be used in a wide variety of foods and in combination with the compositions of this invention.
- The following examples are given to illustrate the present invention. It should be understood, however, that the invention is not to be limited to the specific conditions or details described in these examples. Throughout the specification, any and all references to a publicly available document, including a U.S. patent, are specifically incorporated by reference.
- In the examples that follow, the particle sizes were measured using a Horiba LA-910 Laser Scattering Particle Size Distribution Analyzer (Horiba Instruments, Irvine, Calif.). The particle mean and D90 (which is the size below which 90% of the distribution is located) are obtained from a weight distribution. Furthermore, all formulations are given in weight % (w/w).
- Several of the formulations in the examples that follow were also investigated using a light microscope.
- The purpose of this example was to prepare nanoparticulate dispersions of lovastatin, and to test the prepared compositions for stability at varying temperatures.
- Four formulations of lovastatin were milled, as described in Table 1, by milling the components of the compositions under high energy milling conditions in a DYNO®-Mill KDL (Willy A. Bachofen AG, Maschinenfabrik, Basle, Switzerland) for 2 to 3 hours until the desired particle size was achieved.
- Formulation 1 comprised 5% (w/w) lovastatin, 1.25% (w/w) Hydroxypropylcellulose, super-low viscosity grade (HPC-SL), and 0.05% (w/w) dioctyl sodium sulfosuccinate (DOSS).
- Formulation 2 comprised 5% (w/w) lovastatin, 1.25% (w/w) hydroxypropylmethylcellulose (HPMC), and 0.05% (w/w) dioctyl sodium sulfosuccinate (DOSS).
- Formulation 3 comprised 5% (w/w) lovastatin, 1.25% (w/w) Povidone USP, Plasdone® K29/52 (PVPK29\32), and 0.05% (w/w) dioctyl sodium sulfosuccinate (DOSS).
- Formulation 4 comprised 5% (w/w) lovastatin, 1.25% (w/w) Plasdone 5630 (S630), and 0.05% (w/w) dioctyl sodium sulfosuccinate (DOSS).
- The particle size of the resultant compositions was measured using a Horiba LA-910 Laser Scattering Particle Size Distribution Analyzer ((Horiba Instruments, Irvine, Calif.).
-
TABLE I Post-Milling Stability Stability Stability Formu- Particle Size Particle Size @ Particle Size @ Particle Size @ lation (nm) 5 C (nm) 25 C (nm) 40 C (nm) #1 Mean: 165 Mean: 184 Mean: 188 Mean: 205 D90: 218 4 weeks D90: 247 D90: 264 4 weeks 4 weeks #2 Mean: 174 Mean: 183 Mean: 191 Mean: 213 D90: 227 D90: 241 D90: 253 D90: 280 4 weeks 4 weeks 4 weeks #3 Mean: 173 Mean: 169 Mean: 179 Mean: 193 D90: 229 D90: 223 D90: 237 D90: 252/ 4 weeks 4 weeks 4 weeks #4 Mean: 165 Mean: 165 Mean: 187 Mean: 235 D90: 218 D90: 220 D90: 246 D90: 310 4 weeks 4 weeks 4 weeks
The results of this experiment show that all formulations or compositions were stable. - As described in the literature (Pharmazie, Volume 56, September 2001, p 738-740), lovastatin has a potential for oxidative degradation. To determine which of the formulations exhibited the least amount of degradants an HPLC analysis was performed on the compositions prepared in Example 1.
- The method was a reversed phase HPLC method based on an existing assay method found in the literature (Pharmazie, Volume 56, September 2001, p 738-740). The results of these sample runs were compared to an active pharmaceutical ingredient (API), commercially available lovastatin, standard to determine which milled sample was least oxidized.
- Analysis took place after 4-5 weeks of storage. The four different samples were compared to an API standard. For this comparison three factors were used to determine which formulation was optimal: (1) the percent lovastatin, (2) overall appearance of impurity profile, and (3) the percent area of the peak at RRT 0.87. This peak was selected was because it had the largest area of all the impurity peaks and seemed to increase as the area of the lovastatin peak decreased.
- Formulation #2 containing HPMC compared the best with the API standard. Both had similar amount of impurities, percent lovastain, and comparable peak areas at RRT 0.87. The sample containing PVP K29/32 had the highest amount of impurities, lowest percent lovastatin, and the largest peak area at RRT 0.87.
- The results of this experiment showed that the formulation containing HPMC yielded the best impurity profile. No significant differences from the lovastatin API profile were observed, indicating minimal oxidative degradation occurred during milling or subsequent storage.
- The purpose of this example was to evaluate the efficacy of nanoparticulate lovastatin compositions.
- New Zealand White rabbits were fed a diet enriched with 1% cholesterol for four weeks. At the four week time point the animals were maintained on a high cholesterol diet but were dosed (in the fed state) each day for a additional four week period with 6 mg/kg dose of either suspensions of Formulation #2 (Example 1) or commercially available lovastatin (Mevacor®) tablets mortarized into a crude suspension comprising the same quantities of HPMC and DOSS as Formulation #2. Placebo also comprised the same quantities of HPMC and DOSS as formulation #2.
- Blood samples for total cholesterol analysis were taken at −2, 0, 2, & 4 weeks after dosing. Total change in cholesterol for each group was as follows:
- 1. Mevacor® mortarized tablets dosed as a liquid suspension: −17.8% (N=6) 2. Formulation #2 dosed as a liquid suspension: −23.2% (N=8) 3. Placebo dosed as a liquid suspension: −12.3 (N=4) 4. Diet enriched with 1% cholesterol (not dosed): +0.10 (N=4) Blood samples for liver activity (37.8 U of ALAT liver enzyme activity) showed the following percentage of rabbits above 3× normal levels as follows: 1. Mevacor® mortarized tablets dosed as a liquid: 20% (N=6)
- 2. Formulation #2 dosed as a liquid suspension: 7.6% (N=8)
- 3. Placebo dosed as a liquid: 0 (N=4)
- The results indicate that Formulation #2 shows greater efficacy and lower liver toxicity trends than the other two groups measured.
- It will be apparent to those skilled in the art that various modifications and variations can be made in the methods and compositions of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.
Claims (54)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/367,716 US20110027371A1 (en) | 1998-10-01 | 2006-03-06 | Nanoparticulate statin formulations and novel statin combinations |
US11/980,586 US20080213378A1 (en) | 1998-10-01 | 2007-10-31 | Nanoparticulate statin formulations and novel statin combinations |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16435198A | 1998-10-01 | 1998-10-01 | |
US09/337,675 US8293277B2 (en) | 1998-10-01 | 1999-06-22 | Controlled-release nanoparticulate compositions |
US38740402P | 2002-06-10 | 2002-06-10 | |
US45781003A | 2003-06-10 | 2003-06-10 | |
US11/367,716 US20110027371A1 (en) | 1998-10-01 | 2006-03-06 | Nanoparticulate statin formulations and novel statin combinations |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/337,675 Continuation US8293277B2 (en) | 1998-10-01 | 1999-06-22 | Controlled-release nanoparticulate compositions |
US45781003A Continuation | 1998-10-01 | 2003-06-10 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/980,586 Continuation US20080213378A1 (en) | 1998-10-01 | 2007-10-31 | Nanoparticulate statin formulations and novel statin combinations |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110027371A1 true US20110027371A1 (en) | 2011-02-03 |
Family
ID=23321532
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/337,675 Expired - Fee Related US8293277B2 (en) | 1998-10-01 | 1999-06-22 | Controlled-release nanoparticulate compositions |
US11/367,716 Abandoned US20110027371A1 (en) | 1998-10-01 | 2006-03-06 | Nanoparticulate statin formulations and novel statin combinations |
US13/620,570 Abandoned US20130011447A1 (en) | 1998-10-01 | 2012-09-14 | Controlled release nanoparticulate compositions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/337,675 Expired - Fee Related US8293277B2 (en) | 1998-10-01 | 1999-06-22 | Controlled-release nanoparticulate compositions |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/620,570 Abandoned US20130011447A1 (en) | 1998-10-01 | 2012-09-14 | Controlled release nanoparticulate compositions |
Country Status (1)
Country | Link |
---|---|
US (3) | US8293277B2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100086602A1 (en) * | 2006-08-30 | 2010-04-08 | Kensuke Egashira | Pharmaceutical composition containing statin-encapsulated nanoparticle |
WO2011146583A2 (en) | 2010-05-19 | 2011-11-24 | Elan Pharma International Limited | Nanoparticulate cinacalcet formulations |
US8309136B2 (en) | 2000-09-21 | 2012-11-13 | Alkermes Pharma Ireland Limited | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions |
WO2014195900A2 (en) * | 2013-06-05 | 2014-12-11 | Alparis S.A. De C.V. | Oral pharmaceutical compositions for use in dyslipidemias |
US9974767B2 (en) | 2014-07-14 | 2018-05-22 | University Of Washington | Statins in the treatment of muscular dystrophies and myopathies |
Families Citing this family (181)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA72189C2 (en) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form |
US8236352B2 (en) * | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US20080213378A1 (en) * | 1998-10-01 | 2008-09-04 | Elan Pharma International, Ltd. | Nanoparticulate statin formulations and novel statin combinations |
WO2000018374A1 (en) * | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
US20040013613A1 (en) * | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
US20090297597A1 (en) * | 1998-11-02 | 2009-12-03 | Gary Liversidge | Modified Release Ticlopidine Compositions |
US20060240105A1 (en) * | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
JP4613275B2 (en) * | 1998-11-02 | 2011-01-12 | エラン ファーマ インターナショナル,リミティド | Multiparticulate modified release composition |
US20090297602A1 (en) * | 1998-11-02 | 2009-12-03 | Devane John G | Modified Release Loxoprofen Compositions |
US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US20040141925A1 (en) * | 1998-11-12 | 2004-07-22 | Elan Pharma International Ltd. | Novel triamcinolone compositions |
US6428814B1 (en) * | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
ID29270A (en) * | 1998-11-20 | 2001-08-16 | Rtp Pharma Inc | MICRO PARTICLES THAT ARE STABILIZED BY PHOSPHOLIPIDS THAT CAN SPREAD |
US20040115134A1 (en) * | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
EP2269587A1 (en) | 1999-10-29 | 2011-01-05 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
US8586094B2 (en) * | 2000-09-20 | 2013-11-19 | Jagotec Ag | Coated tablets |
US7998507B2 (en) * | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
US7276249B2 (en) * | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US20080241070A1 (en) * | 2000-09-21 | 2008-10-02 | Elan Pharma International Ltd. | Fenofibrate dosage forms |
US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
AU2738302A (en) | 2000-10-30 | 2002-05-15 | Euro Celtique Sa | Controlled release hydrocodone formulations |
US20050048126A1 (en) * | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
US20030072807A1 (en) * | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US9700866B2 (en) * | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US6951656B2 (en) | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US6884436B2 (en) * | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
CA2434835A1 (en) * | 2001-02-13 | 2002-08-22 | Astrazeneca Ab | Novel modified released formulation |
US6976647B2 (en) * | 2001-06-05 | 2005-12-20 | Elan Pharma International, Limited | System and method for milling materials |
BR0211028A (en) * | 2001-06-22 | 2004-06-15 | Pfizer Prod Inc | Aqueous solution, method for forming drug and polymer combinations, pharmaceutical compositions, method for forming a pharmaceutical composition and product |
DE60203506T2 (en) * | 2001-06-22 | 2006-02-16 | Marie Lindner | HIGH-BY-STEP SCREENING PROCEDURE USING LABORATORY MILLS OR MICROFLUIDICS |
US6720002B2 (en) * | 2001-07-20 | 2004-04-13 | R.P. Scherer Technologies, Inc. | Antihistamine formulations for soft capsule dosage forms |
AR034813A1 (en) * | 2001-07-20 | 2004-03-17 | Novartis Ag | PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME |
JP4464129B2 (en) * | 2001-09-19 | 2010-05-19 | エラン ファーマ インターナショナル,リミティド | Nanoparticulate insulin preparation |
IL160570A0 (en) * | 2001-09-26 | 2004-07-25 | Baxter Int | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
US7838026B2 (en) * | 2001-09-28 | 2010-11-23 | Mcneil-Ppc, Inc. | Burst-release polymer composition and dosage forms comprising the same |
US6908626B2 (en) * | 2001-10-12 | 2005-06-21 | Elan Pharma International Ltd. | Compositions having a combination of immediate release and controlled release characteristics |
US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
GB0127805D0 (en) * | 2001-11-20 | 2002-01-09 | Smithkline Beecham Plc | Pharmaceutical composition |
HUP0501186A2 (en) * | 2001-12-03 | 2006-05-29 | Novacea | Pharmaceutical compositions comprising active vitamin d compounds |
ATE464880T1 (en) | 2002-02-04 | 2010-05-15 | Elan Pharma Int Ltd | MEDICINAL NANOPARTICLES WITH LYSOZYME SURFACE STABILIZER |
US20040101566A1 (en) * | 2002-02-04 | 2004-05-27 | Elan Pharma International Limited | Novel benzoyl peroxide compositions |
GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
JP2005526095A (en) * | 2002-03-20 | 2005-09-02 | エラン ファーマ インターナショナル,リミティド | Rapid dissolution dosage form with low friability |
WO2003080027A1 (en) * | 2002-03-20 | 2003-10-02 | Elan Pharma International, Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
US20080220075A1 (en) * | 2002-03-20 | 2008-09-11 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
PT1494649E (en) | 2002-04-12 | 2012-04-11 | Alkermes Pharma Ireland Ltd | Nanoparticulate megestrol formulations |
US20100226989A1 (en) * | 2002-04-12 | 2010-09-09 | Elan Pharma International, Limited | Nanoparticulate megestrol formulations |
US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
US20040105889A1 (en) * | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
US20040096498A1 (en) * | 2002-04-29 | 2004-05-20 | Alvin Kershman | Oral pharmaceutical delivery system with improved sustained release |
DE60325718D1 (en) * | 2002-05-06 | 2009-02-26 | Elan Pharma Int Ltd | Nystatin NANOPARTICLE COMPOSITIONS |
US20070264348A1 (en) * | 2002-05-24 | 2007-11-15 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US6863852B1 (en) | 2002-05-30 | 2005-03-08 | Zeus Industrial Products, Inc. | Fluoropolymer extrusions based on novel combinations of process parameters and clay minerals |
US7939102B2 (en) * | 2002-06-07 | 2011-05-10 | Torrent Pharmaceuticals Ltd. | Controlled release formulation of lamotrigine |
CA2488617A1 (en) * | 2002-06-10 | 2003-12-18 | Eugene R. Cooper | Nanoparticulate sterol formulations and sterol combinations |
US7763278B2 (en) * | 2002-06-10 | 2010-07-27 | Elan Pharma International Ltd. | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
CA2492488A1 (en) | 2002-07-16 | 2004-01-22 | Elan Pharma International, Ltd. | Liquid dosage compositions of stable nanoparticulate active agents |
US8637512B2 (en) * | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
EP1553927B9 (en) * | 2002-09-11 | 2011-09-21 | Elan Pharma International Limited | Gel-stabilized nanoparticulate active agent compositions |
US20040105778A1 (en) * | 2002-10-04 | 2004-06-03 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
ATE514418T1 (en) * | 2002-11-12 | 2011-07-15 | Elan Pharma Int Ltd | RAPIDLY DISRUPTING SOLID DOSAGE FORMS WITH NON-FRUABLE CONSISTENCY AND PULLULAN |
US20080305177A1 (en) * | 2002-11-14 | 2008-12-11 | Alvin Kershman | Method of administering testosterone |
WO2004043434A1 (en) * | 2002-11-14 | 2004-05-27 | Shear/Kershman Laboratories, Inc. | Oral testosterone delivery system with improved sustained release |
US20050026877A1 (en) * | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
WO2004058216A2 (en) * | 2002-12-17 | 2004-07-15 | Elan Pharma International Ltd. | Milling microgram quantities of nanoparticulate candidate compounds |
JP4469846B2 (en) * | 2003-01-31 | 2010-06-02 | エラン ファーマ インターナショナル,リミティド | Nanoparticulate topiramate formulation |
US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
US20100297252A1 (en) | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
US8512727B2 (en) * | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
US7511079B2 (en) * | 2003-03-24 | 2009-03-31 | Baxter International Inc. | Methods and apparatuses for the comminution and stabilization of small particles |
BRPI0408999A (en) * | 2003-04-04 | 2006-03-28 | Pharmacia Corp | compressed prolonged oral release multiparticulate tablets |
US7786049B2 (en) * | 2003-04-10 | 2010-08-31 | Halliburton Energy Services, Inc. | Drilling fluids with improved shale inhibition and methods of drilling in subterranean formations |
CA2523035C (en) * | 2003-05-22 | 2011-04-26 | Elan Pharma International Ltd. | Sterilization of dispersions of nanoparticulate active agents with gamma radiation |
US20050020546A1 (en) * | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
WO2005016310A1 (en) * | 2003-08-08 | 2005-02-24 | Elan Pharma International Ltd. | Novel metaxalone compositions |
GB0320854D0 (en) | 2003-09-05 | 2003-10-08 | Arrow No 7 Ltd | Buccal drug delivery |
EP1686962B9 (en) * | 2003-11-05 | 2012-10-03 | Elan Pharma International Limited | Nanoparticulate compositions having a peptide as a surface stabilizer |
US7943585B2 (en) | 2003-12-22 | 2011-05-17 | Sandoz, Inc. | Extended release antibiotic composition |
EP1730516A1 (en) * | 2004-03-30 | 2006-12-13 | Pfizer Products Incorporated | Method and device for evaluation of pharmaceutical compositions |
CA2564960A1 (en) * | 2004-05-21 | 2005-12-01 | Lawrence Solomon | Pharmaceutical tablets having a separation mark positioned on the side of said tablets |
US20060052370A1 (en) * | 2004-08-24 | 2006-03-09 | Meyerson Laurence R | Methods and compositions for treating nociceptive pain |
AU2005278894A1 (en) | 2004-08-31 | 2006-03-09 | Pfizer Products Inc. | Pharmaceutical dosage forms comprising a low-solubility drug and a polymer |
CN101106972A (en) * | 2004-11-16 | 2008-01-16 | 伊兰制药国际有限公司 | Injectable nanoparticulate olanzapine formulations |
UA89513C2 (en) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Nanoparticulate raloxifene hydrochloride composition |
KR20070116581A (en) * | 2004-12-15 | 2007-12-10 | 엘란 파마 인터내셔널 리미티드 | Nanoparticulate tacrolimus formulations |
WO2006069098A1 (en) * | 2004-12-22 | 2006-06-29 | Elan Pharma International Ltd. | Nanoparticulate bicalutamide formulations |
WO2006074218A2 (en) * | 2005-01-06 | 2006-07-13 | Elan Pharma International Ltd. | Nanoparticulate candesartan formulations |
KR20070112164A (en) | 2005-02-15 | 2007-11-22 | 엘란 파마 인터내셔널 리미티드 | Aerosol and injectable formulations of nanoparticulate benzodiazepine |
US20080254114A1 (en) * | 2005-03-03 | 2008-10-16 | Elan Corporation Plc | Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles |
US20060204588A1 (en) * | 2005-03-10 | 2006-09-14 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof |
JP2008533174A (en) * | 2005-03-16 | 2008-08-21 | エラン ファーマ インターナショナル リミテッド | Nanoparticulate leukotriene receptor antagonist / corticosteroid preparation |
MX2007011495A (en) * | 2005-03-17 | 2007-12-06 | Elan Pharma Int Ltd | Nanoparticulate biphosphonate compositions. |
EA200702049A1 (en) * | 2005-03-23 | 2008-02-28 | Элан Фарма Интернэшнл Лтд. | COMPOSITIONS OF CORTICOSTEROID NANOPARTICLES WITH ANTIGISTAMINS |
US20060246141A1 (en) * | 2005-04-12 | 2006-11-02 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
CA2603084A1 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cyclosporine |
CA2604735A1 (en) | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Nanoparticulate quinazoline derivative formulations |
US7943555B2 (en) * | 2005-04-19 | 2011-05-17 | Halliburton Energy Services Inc. | Wellbore treatment kits for forming a polymeric precipitate to reduce the loss of fluid to a subterranean formation |
US7905287B2 (en) | 2005-04-19 | 2011-03-15 | Halliburton Energy Services Inc. | Methods of using a polymeric precipitate to reduce the loss of fluid to a subterranean formation |
CA2607494A1 (en) * | 2005-05-10 | 2007-08-02 | Elan Pharma International Limited | Nanoparticulate clopidogrel formulations |
WO2006132752A1 (en) * | 2005-05-10 | 2006-12-14 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising vitamin k2 |
US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
WO2006133045A1 (en) * | 2005-06-03 | 2006-12-14 | Elan Pharma International, Limited | Nanoparticulate benidipine compositions |
CA2610480A1 (en) * | 2005-06-03 | 2007-05-10 | Scott Jenkins | Nanoparticulate acetaminophen formulations |
JP2009517485A (en) | 2005-06-08 | 2009-04-30 | エラン・ファルマ・インターナショナル・リミテッド | Nanoparticulate and controlled release compositions containing cefditoren |
EP1898882B1 (en) * | 2005-06-09 | 2009-10-28 | Elan Pharma International Limited | Nanoparticulate ebastine formulations |
BRPI0611626A2 (en) * | 2005-06-13 | 2010-09-21 | Elan Pharma Int Ltd | Combination Formulations of Clopidogrel and Aspirin Nanoparticles |
US20060280787A1 (en) * | 2005-06-14 | 2006-12-14 | Baxter International Inc. | Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof |
EP1931340A2 (en) * | 2005-06-15 | 2008-06-18 | Elan Pharma International Limited | Nanoparticulate azelnidipine formulations |
CA2613474A1 (en) * | 2005-06-20 | 2007-03-08 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds |
EP1904041A2 (en) * | 2005-07-07 | 2008-04-02 | Elan Pharma International Limited | Nanoparticulate clarithromycin formulations |
US7833945B2 (en) * | 2005-07-15 | 2010-11-16 | Halliburton Energy Services Inc. | Treatment fluids with improved shale inhibition and methods of use in subterranean operations |
CA2622200A1 (en) * | 2005-09-13 | 2007-03-22 | Elan Pharma International, Limited | Nanoparticulate tadalafil formulations |
EP1933814A2 (en) * | 2005-09-15 | 2008-06-25 | Elan Pharma International Limited | Nanoparticulate aripiprazole formulations |
EP1954245A2 (en) * | 2005-11-15 | 2008-08-13 | Baxter International Inc. | Compositions of lipoxygenase inhibitors |
KR101405545B1 (en) | 2005-11-28 | 2014-07-03 | 마리누스 파마슈티컬스 | Ganaxolone formulations and methods for the making and use thereof |
US20070141148A1 (en) * | 2005-11-30 | 2007-06-21 | Merz Pharma Gmbh & Co. Kgaa | Neramexane MR matrix tablet |
US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
US20070231381A1 (en) * | 2006-03-31 | 2007-10-04 | Sherman Bernard C | Controlled-release dosage forms comprising zolpidem or a salt thereof |
PL2010158T3 (en) * | 2006-04-26 | 2016-09-30 | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix | |
BRPI0712130A2 (en) * | 2006-05-30 | 2012-01-17 | Elan Pharma Int Ltd | nanoparticulate posaconazole formulations |
AU2007264418B2 (en) | 2006-06-30 | 2012-05-03 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
US20080213374A1 (en) * | 2006-07-10 | 2008-09-04 | Elan Pharma International Limited | Nanoparticulate sorafenib formulations |
AU2007272501A1 (en) * | 2006-07-12 | 2008-01-17 | Elan Pharma International Limited | Nanoparticulate formulations of modafinil |
AU2007325628A1 (en) | 2006-11-28 | 2008-06-05 | Marinus Pharmaceuticals | Nanoparticulate formulations and methods for the making and use thereof |
WO2008065502A1 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein |
US20090152176A1 (en) * | 2006-12-23 | 2009-06-18 | Baxter International Inc. | Magnetic separation of fine particles from compositions |
JP2010521494A (en) * | 2007-03-16 | 2010-06-24 | エラン・ファルマ・インターナショナル・リミテッド | Combination of narcotic and non-narcotic analgesics |
WO2008125940A2 (en) * | 2007-04-17 | 2008-10-23 | Pfizer Products Inc. | Nanoparticles comprising non-crystalline drug |
WO2008135828A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
US8703204B2 (en) * | 2007-05-03 | 2014-04-22 | Bend Research, Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer |
WO2008135852A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Pharmaceutical compositions comprising nanoparticles and casein |
US20080293814A1 (en) * | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
US8426467B2 (en) * | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
US8722736B2 (en) * | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
EP2162120B1 (en) * | 2007-06-04 | 2016-05-04 | Bend Research, Inc | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
WO2008149230A2 (en) | 2007-06-04 | 2008-12-11 | Pfizer Products Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate |
US20100215747A1 (en) * | 2007-07-13 | 2010-08-26 | Corey Jay Bloom | Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers |
AU2014277657B2 (en) * | 2007-09-03 | 2016-09-29 | Nanoshift, Llc | Particulate Compositions for Delivery of Poorly Soluble Drugs |
AU2008296971B2 (en) * | 2007-09-03 | 2014-10-02 | Nanoshift, Llc | Particulate compositions for delivery of poorly soluble drugs |
US8642062B2 (en) | 2007-10-31 | 2014-02-04 | Abbott Cardiovascular Systems Inc. | Implantable device having a slow dissolving polymer |
EP2231169B1 (en) * | 2007-12-06 | 2016-05-04 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
EP2240162A4 (en) * | 2007-12-06 | 2013-10-09 | Bend Res Inc | Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer |
MY159208A (en) | 2009-04-24 | 2016-12-30 | Iceutica Pty Ltd | A novel formulation of indomethacin |
TWI478733B (en) * | 2009-05-13 | 2015-04-01 | Wyeth Llc | Burst drug release compositions |
JP6072539B2 (en) | 2009-05-27 | 2017-02-01 | アルカーメス ファーマ アイルランド リミテッド | Reduction of flaky aggregation in nanoparticulate active agent compositions |
FR2945950A1 (en) | 2009-05-27 | 2010-12-03 | Elan Pharma Int Ltd | ANTICANCER NANOPARTICLE COMPOSITIONS AND METHODS FOR PREPARING THE SAME |
WO2011086047A1 (en) | 2010-01-13 | 2011-07-21 | Azur Pharma Limited | Method for titrating clozapine |
EP2826468A1 (en) | 2010-12-22 | 2015-01-21 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
CN103327969A (en) | 2010-12-23 | 2013-09-25 | 普渡制药公司 | Tamper resistant solid oral dosage forms |
EP3269372B1 (en) | 2012-01-19 | 2019-06-12 | Hybrid Medical, LLC | Topical therapeutic formulations |
US10471131B2 (en) | 2012-01-19 | 2019-11-12 | Hybrid Medical, Llc | Topical therapeutic formulations |
KR101840526B1 (en) | 2013-02-05 | 2018-03-20 | 퍼듀 퍼머 엘피 | Tamper resistant pharmaceutical formulations |
GB201304662D0 (en) * | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US9528066B2 (en) | 2013-08-30 | 2016-12-27 | Halliburton Energy Services, Inc. | High-temperature lubricants comprising elongated carbon nanoparticles for use in subterranean formation operations |
BR112016002318A2 (en) | 2013-08-30 | 2017-08-01 | Halliburton Energy Services Inc | Drill bit, method for drilling underground and high temperature lubricant |
US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
US11688014B1 (en) | 2014-10-02 | 2023-06-27 | United Services Automobile Association (Usaa) | Systems and methods for unmanned vehicle management |
US9939810B1 (en) | 2015-04-17 | 2018-04-10 | United Services Automobile Association | Indoor drone flight awareness system |
CN107709344B (en) | 2015-05-01 | 2022-07-15 | 共晶制药股份有限公司 | Nucleoside analogues for the treatment of flaviviridae and cancer |
US20160346219A1 (en) | 2015-06-01 | 2016-12-01 | Autotelic Llc | Phospholipid-coated therapeutic agent nanoparticles and related methods |
US20180185270A1 (en) * | 2015-06-08 | 2018-07-05 | Zim Laboratories Limited | Mucosal delivery of vitamin b12 |
EP3324930A2 (en) | 2015-09-16 | 2018-05-30 | DFB Soria, LLC | Delivery of drug nanoparticles and methods of use thereof |
EP3343987A4 (en) * | 2015-09-22 | 2018-09-12 | Huawei Technologies Co., Ltd. | Method and device for transmitting uplink control information (uci) in carrier aggregation |
EA036155B1 (en) | 2015-10-16 | 2020-10-06 | Маринус Фармасьютикалс, Инк. | Injectable neurosteroid formulations containing nanoparticles |
WO2017203365A1 (en) * | 2016-05-26 | 2017-11-30 | Dr. Reddy's Laboratiories Ltd. | Pharmaceutical compositions for treating acne |
US20180042903A1 (en) | 2016-08-11 | 2018-02-15 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
WO2018170196A1 (en) | 2017-03-15 | 2018-09-20 | Dfb Soria, Llc | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes |
WO2019178024A1 (en) | 2018-03-16 | 2019-09-19 | Dfb Soria, Llc | Topical therapy for the treatment of cervical intraepithelial neoplasia (cin) and cervical cancer using nanoparticles of taxanes |
US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
MX2022001553A (en) | 2019-08-05 | 2022-04-18 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treatment of status epilepticus. |
MX2022006014A (en) | 2019-12-06 | 2022-06-22 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating tuberous sclerosis complex. |
EP3928772A1 (en) | 2020-06-26 | 2021-12-29 | Algiax Pharmaceuticals GmbH | Nanoparticulate composition |
CN113069589A (en) * | 2021-02-22 | 2021-07-06 | 中国科学院大学温州研究院(温州生物材料与工程研究所) | Biodegradable antibacterial hemostatic sponge |
Citations (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3269798A (en) * | 1962-01-26 | 1966-08-30 | Preston John Miles | Stabilized phosphoric acid |
US4346227A (en) * | 1980-06-06 | 1982-08-24 | Sankyo Company, Limited | ML-236B Derivatives and their preparation |
US4389397A (en) * | 1980-08-04 | 1983-06-21 | Merck & Co., Inc. | Solubilization of ivermectin in water |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4499289A (en) * | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
US4524060A (en) * | 1981-05-21 | 1985-06-18 | John Wyeth & Brother Limited | Slow release pharmaceutical composition |
US4647576A (en) * | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
US4657901A (en) * | 1983-09-07 | 1987-04-14 | Sheiseido Company, Ltd. | Pharmaceutical composition |
US4665081A (en) * | 1982-12-02 | 1987-05-12 | Takada Seiyaku Kabushiki Kaisha | Solid nifedipine preparations and a process for preparing same |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US4686237A (en) * | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
US4727077A (en) * | 1985-02-20 | 1988-02-23 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compounds, process for their production, and antitumorous compositions containing them |
US4757059A (en) * | 1984-08-14 | 1988-07-12 | International Copper Research Association | Method for treating convulsions and epilepsy with organic copper compounds |
US4765990A (en) * | 1981-09-14 | 1988-08-23 | Kanebo, Ltd | Sustained-release nifedipine preparation |
US4814175A (en) * | 1986-03-21 | 1989-03-21 | Schering Aktiengesellschaft | Nifedipine combination preparation |
US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
US4851421A (en) * | 1984-09-05 | 1989-07-25 | Kao Corporation | Biocidal fine powder and a suspension containing the same |
US4904668A (en) * | 1986-09-29 | 1990-02-27 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compound |
US4917816A (en) * | 1984-01-03 | 1990-04-17 | Abco Industries, Inc. | Stabilized peroxide compositions and process for producing same |
US4983605A (en) * | 1986-10-23 | 1991-01-08 | Ishihara Sangyo Kaisha Ltd. | Pharmaceutical composition |
US5002952A (en) * | 1986-02-08 | 1991-03-26 | Ishihara Sangyo Kaisha Ltd. | Readily absorbed pharmaceutical composition |
US5027843A (en) * | 1990-06-19 | 1991-07-02 | Conoco Inc. | Use of a water soluble drag reducer in a water/oil/gas system |
US5098907A (en) * | 1989-01-24 | 1992-03-24 | Ishihara Sangyo Kaisha Ltd. | Powdery pharmaceutical composition containing benzoyl urea, a dispersant and silicic acid |
US5118528A (en) * | 1986-12-31 | 1992-06-02 | Centre National De La Recherche Scientifique | Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles |
US5133908A (en) * | 1986-12-31 | 1992-07-28 | Centre National De La Recherche Scientifique (Cnrs) | Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles |
US5298262A (en) * | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US5318767A (en) * | 1991-01-25 | 1994-06-07 | Sterling Winthrop Inc. | X-ray contrast compositions useful in medical imaging |
US5326552A (en) * | 1992-12-17 | 1994-07-05 | Sterling Winthrop Inc. | Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants |
US5328404A (en) * | 1993-03-29 | 1994-07-12 | Sterling Winthrop Inc. | Method of x-ray imaging using iodinated aromatic propanedioates |
US5338761A (en) * | 1988-09-29 | 1994-08-16 | Shiseido Company Ltd. | Emulsified composition |
US5340564A (en) * | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5399353A (en) * | 1986-06-20 | 1995-03-21 | Henkel Kommanditgesellschaft Auf Aktien | Preparations for covering undamaged and/or damaged areas of human or animal skin |
US5401492A (en) * | 1992-12-17 | 1995-03-28 | Sterling Winthrop, Inc. | Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents |
US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5500204A (en) * | 1995-02-10 | 1996-03-19 | Eastman Kodak Company | Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging |
US5503723A (en) * | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5518187A (en) * | 1992-11-25 | 1996-05-21 | Nano Systems L.L.C. | Method of grinding pharmaceutical substances |
US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5518739A (en) * | 1994-07-20 | 1996-05-21 | The Wm. Wrigley Jr. Company | Chewing gum containing low levels of maltodextrin |
US5521168A (en) * | 1994-10-13 | 1996-05-28 | Alcon Laboratories, Inc. | Estrogen metabolites for lowering intraocular pressure |
US5521218A (en) * | 1995-05-15 | 1996-05-28 | Nanosystems L.L.C. | Nanoparticulate iodipamide derivatives for use as x-ray contrast agents |
US5525328A (en) * | 1994-06-24 | 1996-06-11 | Nanosystems L.L.C. | Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging |
US5527545A (en) * | 1989-09-18 | 1996-06-18 | Recordati S.A. Chemical And Pharmaceutical Company | Liquid-suspension controlled-release pharmaceutical composition |
US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5543133A (en) * | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5593657A (en) * | 1995-02-09 | 1997-01-14 | Nanosystems L.L.C. | Barium salt formulations stabilized by non-ionic and anionic stabilizers |
US5595762A (en) * | 1992-11-30 | 1997-01-21 | Laboratoires Virbac | Stabilized pulverulent active agents, compositions containing them, process for obtaining them and their applications |
US5622938A (en) * | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
US5628981A (en) * | 1994-12-30 | 1997-05-13 | Nano Systems L.L.C. | Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents |
US5632996A (en) * | 1995-04-14 | 1997-05-27 | Imaginative Research Associates, Inc. | Benzoyl peroxide and benzoate ester containing compositions suitable for contact with skin |
US5643552A (en) * | 1995-03-09 | 1997-07-01 | Nanosystems L.L.C. | Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging |
US5656299A (en) * | 1992-11-17 | 1997-08-12 | Yoshitomi Pharmaceutical Industries, Ltd. | Sustained release microsphere preparation containing antipsychotic drug and production process thereof |
US5718919A (en) * | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US5718388A (en) * | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
US5719197A (en) * | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5741522A (en) * | 1991-07-05 | 1998-04-21 | University Of Rochester | Ultrasmall, non-aggregated porous particles of uniform size for entrapping gas bubbles within and methods |
US5747001A (en) * | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
US5756546A (en) * | 1994-06-16 | 1998-05-26 | Pirotte; Bernard | Water-soluble nimesulide salt and its preparation, aqueous dolution containing it, nimesulide-based combinations and their uses |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US5862999A (en) * | 1994-05-25 | 1999-01-26 | Nano Systems L.L.C. | Method of grinding pharmaceutical substances |
US5871747A (en) * | 1992-09-11 | 1999-02-16 | Institut Pasteur | Antigen-carrying microparticles and their use in the indication of humoral or cellular responses |
US5889088A (en) * | 1996-02-09 | 1999-03-30 | Hodogaya Chemical Co., Ltd. | Composite particle aqueous suspension and process for producing same |
US5904929A (en) * | 1996-12-25 | 1999-05-18 | Janssen Pharmaceutica, N.V. | Acylated cyclodextrin-containing pharmaceutical composition |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5939091A (en) * | 1997-05-20 | 1999-08-17 | Warner Lambert Company | Method for making fast-melt tablets |
US6017932A (en) * | 1996-12-12 | 2000-01-25 | Panacea Biotec Limited | Pharmaceutical compositions containing at least one NSAID having increased bioavailability |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
US6068858A (en) * | 1997-02-13 | 2000-05-30 | Elan Pharma International Limited | Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
US6090830A (en) * | 1997-10-07 | 2000-07-18 | Fuisz International Ltd. | Controlled release compositions and methods for the treatment of hyperlipidemia |
US6177103B1 (en) * | 1998-06-19 | 2001-01-23 | Rtp Pharma, Inc. | Processes to generate submicron particles of water-insoluble compounds |
US6177104B1 (en) * | 1994-01-27 | 2001-01-23 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving dosage form |
US6193960B1 (en) * | 1996-07-08 | 2001-02-27 | Ciba Specialty Chemicals Corporation | Triazine derivatives |
US6264922B1 (en) * | 1995-02-24 | 2001-07-24 | Elan Pharma International Ltd. | Nebulized aerosols containing nanoparticle dispersions |
US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
US6270806B1 (en) * | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
US20020002294A1 (en) * | 1997-09-24 | 2002-01-03 | D' Amato Robert J. | Estrogenic compounds as antiangiogenic agents |
US20020012675A1 (en) * | 1998-10-01 | 2002-01-31 | Rajeev A. Jain | Controlled-release nanoparticulate compositions |
US6368620B2 (en) * | 1999-06-11 | 2002-04-09 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
US6376986B1 (en) * | 1999-05-11 | 2002-04-23 | Fujitsu Limited | Plasma display panel |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US20020055462A1 (en) * | 1999-06-10 | 2002-05-09 | Reed Michael John | Use |
US20020056206A1 (en) * | 2000-09-20 | 2002-05-16 | Pace Gary W. | Spray drying process and compositions of fenofibrate |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US20030077329A1 (en) * | 2001-10-19 | 2003-04-24 | Kipp James E | Composition of and method for preparing stable particles in a frozen aqueous matrix |
US20050004049A1 (en) * | 1997-03-11 | 2005-01-06 | Elan Pharma International Limited | Novel griseofulvin compositions |
US7198795B2 (en) * | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3692532A (en) * | 1970-10-27 | 1972-09-19 | David R Shenkenberg | Milk-fruit juice beverage and process for preparing same |
JPS524418B2 (en) | 1971-10-06 | 1977-02-03 | ||
DK143689C (en) | 1975-03-20 | 1982-03-15 | J Kreuter | PROCEDURE FOR THE PREPARATION OF AN ADVERTISED VACCINE |
DE3013839A1 (en) * | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | METHOD FOR PRODUCING AN ACTIVATED PHARMACEUTICAL COMPOSITION |
JPS5726615A (en) | 1980-07-23 | 1982-02-12 | Grelan Pharmaceut Co Ltd | Improving method for absorbability of slightly soluble drug |
DE3318649A1 (en) * | 1983-05-21 | 1984-11-22 | Bayer Ag, 5090 Leverkusen | TWO-PHASE FORMULATION |
JPH0621066B2 (en) | 1984-03-14 | 1994-03-23 | 杏林製薬株式会社 | Sustained-release pharmaceutical composition of 3-isobutyryl-2-isopropylpyrazolo [1,5-a] pyridine |
DE3421468A1 (en) * | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | LIPID NANOPELLETS AS A CARRIER SYSTEM FOR MEDICINAL PRODUCTS FOR PERORAL USE |
US4783484A (en) | 1984-10-05 | 1988-11-08 | University Of Rochester | Particulate composition and use thereof as antimicrobial agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
SE455836B (en) | 1985-10-11 | 1988-08-15 | Haessle Ab | PREPARATION WITH CONTROLLED RELEASE CONTAINING A SALT OF METOPROLOL AND METHOD FOR PREPARING THIS PREPARATION |
IT1187751B (en) | 1985-10-15 | 1987-12-23 | Eurand Spa | PROCEDURE FOR THE PREPARATION OF SOLID FORMULATIONS OF NIFEDIPINE WITH HIGH BIO AVAILABILITY AND WITH PROLONGED EFFECT AND FORMULATIONS SO OBTAINED |
IE58401B1 (en) * | 1986-06-20 | 1993-09-08 | Elan Corp Plc | Controlled absorption pharmaceutical composition |
FR2608942B1 (en) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | PROCESS FOR THE PREPARATION OF COLLOIDAL DISPERSIBLE SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOCAPSULES |
FR2627696B1 (en) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | NEW GALENIC FORM OF FENOFIBRATE |
JP2661709B2 (en) | 1988-07-08 | 1997-10-08 | ダウ・ケミカル日本株式会社 | Production method of highly active pesticide wettable powder |
FR2634376B1 (en) * | 1988-07-21 | 1992-04-17 | Farmalyoc | NOVEL SOLID AND POROUS UNIT FORM COMPRISING MICROPARTICLES AND / OR NANOPARTICLES, AS WELL AS ITS PREPARATION |
US5156767A (en) * | 1990-01-16 | 1992-10-20 | Conoco Inc. | Emulsion breaking using alkylphenol-polyethylene oxide-acrylate polymer coated coalescer material |
US5110605A (en) | 1990-08-21 | 1992-05-05 | Oramed, Inc. | Calcium polycarbophil-alginate controlled release composition and method |
CA2053000C (en) | 1990-10-15 | 1995-08-29 | Michael J. Conder | Biosynthetic production of 6(r)-[2-(8(s)-hydroxy-2(s), 6(r)-dimethyl-1,2,6,7,8,8a(r)-hexahydronaphthyl)-ethyl]-4 (r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-one triol acid by enzymatic hydrolysis of lovastatin acid using an enzyme derived from__lonostachys compactiuscula |
US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5215758A (en) | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
US5188755A (en) * | 1991-10-10 | 1993-02-23 | Block Drug Company | Surface erodible controlled releasing, free standing cleansing block and cleaning method for the domestic water closet |
US5610294A (en) | 1991-10-11 | 1997-03-11 | The Du Pont Merck Pharmaceutical Company | Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors |
US5300739A (en) | 1992-05-26 | 1994-04-05 | Otis Elevator Company | Cyclically varying an elevator car's assigned group in a system where each group has a separate lobby corridor |
US5324351A (en) * | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
US5260478A (en) | 1992-12-08 | 1993-11-09 | Sterling Winthrop Inc. | Iodinated aroyloxy carboxamides |
US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
US5811404A (en) | 1993-05-14 | 1998-09-22 | Cytel Corporation | Sialyl Lex analogues as inhibitors of cellular adhesion |
US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
WO1995022318A1 (en) * | 1994-02-17 | 1995-08-24 | Pankaj Modi | Drugs, vaccines and hormones in polylactide coated microspheres |
US5585108A (en) * | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US5466440A (en) * | 1994-12-30 | 1995-11-14 | Eastman Kodak Company | Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays |
JPH10511957A (en) * | 1995-01-05 | 1998-11-17 | ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン | Surface-modified nanoparticles and methods for their production and use |
US5853756A (en) * | 1995-01-11 | 1998-12-29 | J. B. Chemicals & Pharmaceuticals Limited | Controlled release formulations of Ranitidine |
US5573783A (en) * | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
US5811388A (en) * | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
US6231888B1 (en) * | 1996-01-18 | 2001-05-15 | Perio Products Ltd. | Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps |
WO1998001117A1 (en) * | 1996-07-08 | 1998-01-15 | Edward Mendell Co., Inc. | Sustained release matrix for high-dose insoluble drugs |
US5972389A (en) * | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
GB9703552D0 (en) * | 1997-02-20 | 1997-04-09 | Dow Corning | Polymerisation of cyclosiloxanes in the presence of fillers |
US5811425A (en) | 1997-03-04 | 1998-09-22 | Abbott Laboratories | Heterocyclic compounds as COX-2 inhibitors |
CN1158071C (en) | 1997-05-30 | 2004-07-21 | 渗透有限公司 | Multi-layered osmotic device |
EP1010435B1 (en) | 1997-09-05 | 2010-11-03 | Maruho K.K. | Nanocapsule preparations for treating intraarticular diseases |
US6458777B1 (en) * | 1998-03-13 | 2002-10-01 | Mucosal Therapeutics Llc | Methods and compositions for treating and preventing mucositis |
WO2000018374A1 (en) * | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
US20070160675A1 (en) * | 1998-11-02 | 2007-07-12 | Elan Corporation, Plc | Nanoparticulate and controlled release compositions comprising a cephalosporin |
ES2367352T3 (en) | 1999-04-28 | 2011-11-02 | Genetics Institute, Llc | TREATMENT OF MEASURING FIBROSIS THE ANTAGONISM OF IL-3 AND THE IL-3 RECEPTOR CHAINS. |
US6656504B1 (en) | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
AR035642A1 (en) | 2000-05-26 | 2004-06-23 | Pharmacia Corp | USE OF A CELECOXIB COMPOSITION FOR QUICK PAIN RELIEF |
JP4295420B2 (en) | 2000-06-01 | 2009-07-15 | 株式会社リコー | Blank page printing method for printer control device |
CA2410526C (en) | 2000-06-02 | 2012-04-17 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
JP2004523552A (en) | 2001-02-22 | 2004-08-05 | スカイファーマ・カナダ・インコーポレーテッド | Fibrate-statin combination with reduced feeding-fasting effect |
RU2311177C2 (en) * | 2001-08-01 | 2007-11-27 | Мерк Патент Гмбх | Inhibitors of integrin for treating ocular diseases |
WO2003080027A1 (en) | 2002-03-20 | 2003-10-02 | Elan Pharma International, Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
EP1800666A1 (en) | 2002-03-20 | 2007-06-27 | Elan Pharma International Limited | Nanoparticulate compositions of angiogenesis inhibitors |
DE60325718D1 (en) | 2002-05-06 | 2009-02-26 | Elan Pharma Int Ltd | Nystatin NANOPARTICLE COMPOSITIONS |
CA2488617A1 (en) | 2002-06-10 | 2003-12-18 | Eugene R. Cooper | Nanoparticulate sterol formulations and sterol combinations |
JP4502318B2 (en) | 2004-06-02 | 2010-07-14 | 河村電器産業株式会社 | Earth leakage breaker |
-
1999
- 1999-06-22 US US09/337,675 patent/US8293277B2/en not_active Expired - Fee Related
-
2006
- 2006-03-06 US US11/367,716 patent/US20110027371A1/en not_active Abandoned
-
2012
- 2012-09-14 US US13/620,570 patent/US20130011447A1/en not_active Abandoned
Patent Citations (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3269798A (en) * | 1962-01-26 | 1966-08-30 | Preston John Miles | Stabilized phosphoric acid |
US4346227A (en) * | 1980-06-06 | 1982-08-24 | Sankyo Company, Limited | ML-236B Derivatives and their preparation |
US4389397A (en) * | 1980-08-04 | 1983-06-21 | Merck & Co., Inc. | Solubilization of ivermectin in water |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4524060A (en) * | 1981-05-21 | 1985-06-18 | John Wyeth & Brother Limited | Slow release pharmaceutical composition |
US4765990A (en) * | 1981-09-14 | 1988-08-23 | Kanebo, Ltd | Sustained-release nifedipine preparation |
US4665081A (en) * | 1982-12-02 | 1987-05-12 | Takada Seiyaku Kabushiki Kaisha | Solid nifedipine preparations and a process for preparing same |
US4499289A (en) * | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
US4657901A (en) * | 1983-09-07 | 1987-04-14 | Sheiseido Company, Ltd. | Pharmaceutical composition |
US4917816A (en) * | 1984-01-03 | 1990-04-17 | Abco Industries, Inc. | Stabilized peroxide compositions and process for producing same |
US4997454A (en) * | 1984-05-21 | 1991-03-05 | The University Of Rochester | Method for making uniformly-sized particles from insoluble compounds |
US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
US4686237A (en) * | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
US4757059A (en) * | 1984-08-14 | 1988-07-12 | International Copper Research Association | Method for treating convulsions and epilepsy with organic copper compounds |
US4851421A (en) * | 1984-09-05 | 1989-07-25 | Kao Corporation | Biocidal fine powder and a suspension containing the same |
US4647576A (en) * | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
US4727077A (en) * | 1985-02-20 | 1988-02-23 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compounds, process for their production, and antitumorous compositions containing them |
US5002952A (en) * | 1986-02-08 | 1991-03-26 | Ishihara Sangyo Kaisha Ltd. | Readily absorbed pharmaceutical composition |
US4814175A (en) * | 1986-03-21 | 1989-03-21 | Schering Aktiengesellschaft | Nifedipine combination preparation |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5399353A (en) * | 1986-06-20 | 1995-03-21 | Henkel Kommanditgesellschaft Auf Aktien | Preparations for covering undamaged and/or damaged areas of human or animal skin |
US4904668A (en) * | 1986-09-29 | 1990-02-27 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compound |
US4983605A (en) * | 1986-10-23 | 1991-01-08 | Ishihara Sangyo Kaisha Ltd. | Pharmaceutical composition |
US5118528A (en) * | 1986-12-31 | 1992-06-02 | Centre National De La Recherche Scientifique | Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles |
US5133908A (en) * | 1986-12-31 | 1992-07-28 | Centre National De La Recherche Scientifique (Cnrs) | Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles |
US5719197A (en) * | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5338761A (en) * | 1988-09-29 | 1994-08-16 | Shiseido Company Ltd. | Emulsified composition |
US5098907A (en) * | 1989-01-24 | 1992-03-24 | Ishihara Sangyo Kaisha Ltd. | Powdery pharmaceutical composition containing benzoyl urea, a dispersant and silicic acid |
US5527545A (en) * | 1989-09-18 | 1996-06-18 | Recordati S.A. Chemical And Pharmaceutical Company | Liquid-suspension controlled-release pharmaceutical composition |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5027843A (en) * | 1990-06-19 | 1991-07-02 | Conoco Inc. | Use of a water soluble drag reducer in a water/oil/gas system |
US5494683A (en) * | 1991-01-25 | 1996-02-27 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5318767A (en) * | 1991-01-25 | 1994-06-07 | Sterling Winthrop Inc. | X-ray contrast compositions useful in medical imaging |
US5741522A (en) * | 1991-07-05 | 1998-04-21 | University Of Rochester | Ultrasmall, non-aggregated porous particles of uniform size for entrapping gas bubbles within and methods |
US5776496A (en) * | 1991-07-05 | 1998-07-07 | University Of Rochester | Ultrasmall porous particles for enhancing ultrasound back scatter |
US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
US5871747A (en) * | 1992-09-11 | 1999-02-16 | Institut Pasteur | Antigen-carrying microparticles and their use in the indication of humoral or cellular responses |
US5656299A (en) * | 1992-11-17 | 1997-08-12 | Yoshitomi Pharmaceutical Industries, Ltd. | Sustained release microsphere preparation containing antipsychotic drug and production process thereof |
US5518187A (en) * | 1992-11-25 | 1996-05-21 | Nano Systems L.L.C. | Method of grinding pharmaceutical substances |
US5595762A (en) * | 1992-11-30 | 1997-01-21 | Laboratoires Virbac | Stabilized pulverulent active agents, compositions containing them, process for obtaining them and their applications |
US5298262A (en) * | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US5340564A (en) * | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5401492A (en) * | 1992-12-17 | 1995-03-28 | Sterling Winthrop, Inc. | Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents |
US5326552A (en) * | 1992-12-17 | 1994-07-05 | Sterling Winthrop Inc. | Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5328404A (en) * | 1993-03-29 | 1994-07-12 | Sterling Winthrop Inc. | Method of x-ray imaging using iodinated aromatic propanedioates |
US6177104B1 (en) * | 1994-01-27 | 2001-01-23 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving dosage form |
US5862999A (en) * | 1994-05-25 | 1999-01-26 | Nano Systems L.L.C. | Method of grinding pharmaceutical substances |
US5718388A (en) * | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
US5756546A (en) * | 1994-06-16 | 1998-05-26 | Pirotte; Bernard | Water-soluble nimesulide salt and its preparation, aqueous dolution containing it, nimesulide-based combinations and their uses |
US5525328A (en) * | 1994-06-24 | 1996-06-11 | Nanosystems L.L.C. | Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging |
US5518739A (en) * | 1994-07-20 | 1996-05-21 | The Wm. Wrigley Jr. Company | Chewing gum containing low levels of maltodextrin |
US5521168A (en) * | 1994-10-13 | 1996-05-28 | Alcon Laboratories, Inc. | Estrogen metabolites for lowering intraocular pressure |
US5628981A (en) * | 1994-12-30 | 1997-05-13 | Nano Systems L.L.C. | Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents |
US5503723A (en) * | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
US5622938A (en) * | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
US5593657A (en) * | 1995-02-09 | 1997-01-14 | Nanosystems L.L.C. | Barium salt formulations stabilized by non-ionic and anionic stabilizers |
US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5500204A (en) * | 1995-02-10 | 1996-03-19 | Eastman Kodak Company | Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging |
US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5543133A (en) * | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5718919A (en) * | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US5747001A (en) * | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
US6264922B1 (en) * | 1995-02-24 | 2001-07-24 | Elan Pharma International Ltd. | Nebulized aerosols containing nanoparticle dispersions |
US5643552A (en) * | 1995-03-09 | 1997-07-01 | Nanosystems L.L.C. | Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging |
US5632996A (en) * | 1995-04-14 | 1997-05-27 | Imaginative Research Associates, Inc. | Benzoyl peroxide and benzoate ester containing compositions suitable for contact with skin |
US5521218A (en) * | 1995-05-15 | 1996-05-28 | Nanosystems L.L.C. | Nanoparticulate iodipamide derivatives for use as x-ray contrast agents |
US5889088A (en) * | 1996-02-09 | 1999-03-30 | Hodogaya Chemical Co., Ltd. | Composite particle aqueous suspension and process for producing same |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US6193960B1 (en) * | 1996-07-08 | 2001-02-27 | Ciba Specialty Chemicals Corporation | Triazine derivatives |
US6017932A (en) * | 1996-12-12 | 2000-01-25 | Panacea Biotec Limited | Pharmaceutical compositions containing at least one NSAID having increased bioavailability |
US5904929A (en) * | 1996-12-25 | 1999-05-18 | Janssen Pharmaceutica, N.V. | Acylated cyclodextrin-containing pharmaceutical composition |
US6068858A (en) * | 1997-02-13 | 2000-05-30 | Elan Pharma International Limited | Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
US6221400B1 (en) * | 1997-02-13 | 2001-04-24 | Elan Pharma International Limited | Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors |
US20050004049A1 (en) * | 1997-03-11 | 2005-01-06 | Elan Pharma International Limited | Novel griseofulvin compositions |
US5939091A (en) * | 1997-05-20 | 1999-08-17 | Warner Lambert Company | Method for making fast-melt tablets |
US20020002294A1 (en) * | 1997-09-24 | 2002-01-03 | D' Amato Robert J. | Estrogenic compounds as antiangiogenic agents |
US6090830A (en) * | 1997-10-07 | 2000-07-18 | Fuisz International Ltd. | Controlled release compositions and methods for the treatment of hyperlipidemia |
US6177103B1 (en) * | 1998-06-19 | 2001-01-23 | Rtp Pharma, Inc. | Processes to generate submicron particles of water-insoluble compounds |
US20020012675A1 (en) * | 1998-10-01 | 2002-01-31 | Rajeev A. Jain | Controlled-release nanoparticulate compositions |
US6270806B1 (en) * | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6376986B1 (en) * | 1999-05-11 | 2002-04-23 | Fujitsu Limited | Plasma display panel |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US20020055462A1 (en) * | 1999-06-10 | 2002-05-09 | Reed Michael John | Use |
US6368620B2 (en) * | 1999-06-11 | 2002-04-09 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US20020056206A1 (en) * | 2000-09-20 | 2002-05-16 | Pace Gary W. | Spray drying process and compositions of fenofibrate |
US6696084B2 (en) * | 2000-09-20 | 2004-02-24 | Rtp Pharma Inc. | Spray drying process and compositions of fenofibrate |
US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
US6592903B2 (en) * | 2000-09-21 | 2003-07-15 | Elan Pharma International Ltd. | Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
US7198795B2 (en) * | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
US20030077329A1 (en) * | 2001-10-19 | 2003-04-24 | Kipp James E | Composition of and method for preparing stable particles in a frozen aqueous matrix |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8309136B2 (en) | 2000-09-21 | 2012-11-13 | Alkermes Pharma Ireland Limited | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions |
US20100086602A1 (en) * | 2006-08-30 | 2010-04-08 | Kensuke Egashira | Pharmaceutical composition containing statin-encapsulated nanoparticle |
US10568860B2 (en) * | 2006-08-30 | 2020-02-25 | Kowa Co., Ltd. | Pharmaceutical composition containing statin-encapsulated nanoparticle |
WO2011146583A2 (en) | 2010-05-19 | 2011-11-24 | Elan Pharma International Limited | Nanoparticulate cinacalcet formulations |
US9012511B2 (en) | 2010-05-19 | 2015-04-21 | Alkermes Pharma Ireland Limited | Nanoparticulate cinacalcet compositions |
WO2014195900A2 (en) * | 2013-06-05 | 2014-12-11 | Alparis S.A. De C.V. | Oral pharmaceutical compositions for use in dyslipidemias |
WO2014195900A3 (en) * | 2013-06-05 | 2015-02-05 | Alparis S.A. De C.V. | Oral pharmaceutical compositions for use in dyslipidemias |
US9974767B2 (en) | 2014-07-14 | 2018-05-22 | University Of Washington | Statins in the treatment of muscular dystrophies and myopathies |
Also Published As
Publication number | Publication date |
---|---|
US20020012675A1 (en) | 2002-01-31 |
US20130011447A1 (en) | 2013-01-10 |
US8293277B2 (en) | 2012-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7763278B2 (en) | Nanoparticulate polycosanol formulations and novel polycosanol combinations | |
US20110027371A1 (en) | Nanoparticulate statin formulations and novel statin combinations | |
CA2488499C (en) | Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions | |
US7931917B2 (en) | Nanoparticulate fibrate formulations | |
CA2487054C (en) | Nanoparticulate fibrate formulations | |
US20040033202A1 (en) | Nanoparticulate sterol formulations and novel sterol combinations | |
US20080213378A1 (en) | Nanoparticulate statin formulations and novel statin combinations | |
AU2006309295B2 (en) | Nanoparticulate acetaminophen formulations | |
US20110159054A1 (en) | Nanoparticulate bicalutamide formulations | |
US20100221327A1 (en) | Nanoparticulate azelnidipine formulations | |
ZA200410209B (en) | Nanoparticulate fibrate formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MORGAN STANLEY SENIOR FUNDING, INC., NEW YORK Free format text: PATENT SECURITY AGREEMENT (FIRST LIEN);ASSIGNORS:ALKERMES, INC.;ALKERMES PHARMA IRELAND LIMITED;ALKERMES CONTROLLED THERAPEUTICS INC.;REEL/FRAME:026994/0186 Effective date: 20110916 Owner name: MORGAN STANLEY SENIOR FUNDING, INC., NEW YORK Free format text: PATENT SECURITY AGREEMENT (SECOND LIEN);ASSIGNORS:ALKERMES, INC.;ALKERMES PHARMA IRELAND LIMITED;ALKERMES CONTROLLED THERAPEUTICS INC.;REEL/FRAME:026994/0245 Effective date: 20110916 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: ALKERMES, INC., MASSACHUSETTS Free format text: RELEASE BY SECURED PARTY (SECOND LIEN);ASSIGNOR:MORGAN STANLEY SENIOR FUNDING, INC.;REEL/FRAME:029116/0379 Effective date: 20120924 Owner name: ALKERMES PHARMA IRELAND LIMITED, IRELAND Free format text: RELEASE BY SECURED PARTY (SECOND LIEN);ASSIGNOR:MORGAN STANLEY SENIOR FUNDING, INC.;REEL/FRAME:029116/0379 Effective date: 20120924 Owner name: ALKERMES CONTROLLED THERAPEUTICS INC., MASSACHUSET Free format text: RELEASE BY SECURED PARTY (SECOND LIEN);ASSIGNOR:MORGAN STANLEY SENIOR FUNDING, INC.;REEL/FRAME:029116/0379 Effective date: 20120924 |